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ABSTRACT
_______________________________________________________________________
THIMEROSAL-INDUCED NEUROTOXICITY: APOPTOSIS
OCCURS THROUGH A MITOCHONDRIAL-MEDIATED PATHWAY
VIA THE JNK SIGNALING PATHWAY
by Michelle L. Herdman

Thimerosal is an organic mercurial containing an ethylmercury moiety attached to the
sulfur atom of thiosalicylate. Since the 1930s, thimerosal has been used as an
antiseptic and a preservative in a wide variety of products, including medicinal
preparations administered to children and pregnant women. Past exposures to
mercurials have indicated that mercury is a neurotoxin, and can also affect the kidney,
skin, eyes, and immune system. Additionally, fetuses exposed to mercurials are more
susceptible to toxicity because the nervous system is continuously developing.
However, despite its widespread use, thimerosal was only studied on a limited basis until
the end of the 1990s. At that time, the use of thimerosal in vaccines began to concern
parents and physicians because of its potential neurotoxicity, creating a controversy
surrounding the question of safety. Consequently, studies with cell culture and animal
models have begun to discern the mechanisms of toxicity of thimerosal. The present
study hypothesized that thimerosal-induced toxicity occurs through the cJun N-terminal
kinase (JNK)/Activator Protein-1 (AP-1) pathway. We used a human neuroblastoma cell
line (SK-N-SH) as a model for neurotoxicity because it has characteristics that resemble
the developing nervous system. SK-N-SH cells treated with thimerosal underwent
apoptosis in a mitochondrial-dependent manner, as demonstrated by release of
cytochrome c, activation of caspases 9 and 3, degradation of poly(ADP)-ribose
polymerase (PARP), DNA condensation and fragmentation, along with release of lactate
dehydrogenase (LDH), which occurs late in apoptosis. Thimerosal-treated cells also
showed activation of the JNK pathway through increases in phosphorylation of JNK and
cJun. However, despite increases in AP-1 transcriptional activity, use of a dominant
negative to cJun (TAM67) showed that AP-1 activation is not essential to thimerosalinduced apoptosis. Use of a cell permeable JNK inhibitor (SP600125) demonstrated
that JNK activation is a necessary component of thimerosal-induced apoptosis. An
additional component of thimerosal toxicity is an increase in oxidative stress.
Antioxidants were used to determine if the oxidative stress component was connected to
the JNK pathway activation. The antioxidant Trolox and the glutathione precursor Nacetylcysteine (NAC) both protected the cells from apoptosis, but served to increase the
phosphorylation of JNK, while still decreasing levels of the proapoptotic protein Bim.
Additionally, the JNK inhibitor decreased levels of the stress-response protein heme
oxygenase-1 (HO-1). These results indicate that while the oxidative stress pathway and
the JNK pathway may be affected by the actions of the other, additional intermediates
are involved.
Taken together, these results present a significant increase in the
cumulative information concerning the mechanism of thimerosal-induced neurotoxicity.
By increasing the overall knowledge base, we provide targets for the development of
methods to attenuate potential neurotoxicity in patients exposed to thimerosal.

iii

DEDICATION
I would like to dedicate this work to my son, Ryan. To Ryan, I thank you for your
sacrifices and patience through all of these years. I hope that you see that hard
work and perseverance do pay off in the end, and I want you to know that even
though my formal education has ended, I know that I will continue to learn from
you each day.

iv

ACKNOWLEDGMENTS
I would like to express my sincerest gratitude to my mentor and advisor, Dr.
Kelley Kiningham.

Her support, guidance, and especially her patience

throughout this project have been invaluable.

I would also like to thank Dr.

Rankin, Dr. Valentovic, Dr. Niles, and Dr. Moore, who have provided valuable
guidance and support for both this project and my education.
Special thanks to Carla Cook and Susie Saunders for their help on this project.
I would like to extend special thanks to Aileen Marcelo for all of her technical
help, friendship, and moral support during this project. I would also like to thank
my fellow students, especially Ava Dykes and Caroline Mills, for their support
during my time at Marshall University.
Finally, I would like to thank my family for all of the help they have given me
during these years. I would not have been able to do this without their help.
Thank you.

v

TABLE OF CONTENTS

ABSTRACT .......................................................................................................................... iii
DEDICATION ........................................................................................................................iv
ACKNOWLEDGMENTS ......................................................................................................v
TABLE OF CONTENTS......................................................................................................vi
LIST OF FIGURES...............................................................................................................ix
LIST OF TABLES.................................................................................................................xi
LIST OF SYMBOLS / NOMENCLATURE .....................................................................xii
CHAPTER I.............................................................................................................................1
INTRODUCTION ......................................................................................................................1
1.1 Thimerosal and Neurotoxicity ...............................................................................1
1.2 Hypothesis................................................................................................................2
1.3 Selection of Neurotoxicity Model .........................................................................2
CHAPTER II............................................................................................................................4
REVIEW OF LITERATURE ......................................................................................................4
2.1 Mercury .....................................................................................................................4
2.2 Thimerosal................................................................................................................9
2.3 cJun N-Terminal Kinase (JNK)/Activator Protein-1 (AP-1)...........................18
2.4 Oxidative Stress ....................................................................................................27
CHAPTER III.........................................................................................................................31
METHODS ............................................................................................................................31
3.1 Cell Line..................................................................................................................31
3.2 Materials .................................................................................................................31
3.3 Characterization of Cell Line...............................................................................32
3.4 Protein Analysis.....................................................................................................35
3.5 Treatment of Cells with Thimerosal...................................................................37
3.6 Cell Viability Assays .............................................................................................37
3.7 Fluorescent Microscopy.......................................................................................38
3.8 Cell Counts for Apoptotic and Necrotic Cells ..................................................39
3.9 Isolation of Cytoplasmic Fractions, Nuclear Extracts, and Whole Cell
Lysates...........................................................................................................................39
3.10 Subcellular Fractionation...................................................................................40
3.11 Caspase-3 Protease Activity ............................................................................40
vi

3.12 Western Analysis ................................................................................................41
3.13 Transient Transfection.......................................................................................42
3.14 Treatment with JNK Inhibitor II (SP600125)..................................................43
3.15 Treatment with Trolox ........................................................................................43
3.16 Treatment with N-Acetylcysteine.....................................................................45
3.17 Statistical Analysis..............................................................................................45
CHAPTER IV ........................................................................................................................46
RESULTS .............................................................................................................................46
4.1 Morphological Changes Upon Thimerosal Treatment...................................46
4.2 Lactate Dehydrogenase (LDH) Assay ..............................................................46
4.3 3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium Bromide (MTT)
Assay..............................................................................................................................48
4.4 Fluorescent Analysis of Cell Death ...................................................................48
4.5 Cell Counts for Apoptotic and Necrotic Cells ..................................................51
4.6 Thimerosal Causes Cytochrome c Translocation from the Mitochondria to
the Cytosol ....................................................................................................................54
4.7 Thimerosal Induces Caspase 9 Cleavage .......................................................54
4.8 Thimerosal Induces Caspase 3 (CPP-32) Cleavage.....................................54
4.9 Caspase 3 Activity Increases in a Concentration- and Time-dependent
Manner...........................................................................................................................58
4.10 Thimerosal Induces Poly(ADP-ribose) Polymerase (PARP) Cleavage...58
4.11 Thimerosal Induces Phosphorylation of JNK ................................................61
4.12 Thimerosal Treatment Causes Increases in cJun and cFos......................61
4.13 Thimerosal Induces Phosphorylation of cJun (Ser 63 and Ser 73) ..........64
4.14 Thimerosal Activates AP-1 Transcriptional Activity Through cJun But Not
cFos................................................................................................................................64
4.15 Thimerosal Treatment Increases Levels of Proapoptotic Bim...................66
4.16 Pretreatment with JNK inhibitor II (SP600125) Blocks Increases in Bim
and Other Apoptotic Proteins ....................................................................................69
4.17 Blockage of cJun Transcriptional Activity Does Not Prevent Apoptosis..69
4.18 JNK Inhibitor II (SP600125) Decreases Heme Oxygenase-1 (HO-1)
Levels.............................................................................................................................72
4.19 Blockage of cJun Transcriptional Activity Does Not Affect HO-1 Levels.72
4.20 Oxidative Stress Component is Upstream of JNK Activation ....................76
4.21 Antioxidants Affect Bim Levels.........................................................................78
CHAPTER V .........................................................................................................................85
DISCUSSION ........................................................................................................................85
5.1 Introduction.............................................................................................................85
5.2 Toxicity Studies .....................................................................................................87
5.3 Apoptosis Studies .................................................................................................88
5.4 JNK/AP-1 Studies .................................................................................................89
5.5 JNK/Oxidative Stress Studies ............................................................................91
5.6 Summary ................................................................................................................93
5.7 Future Studies .......................................................................................................94
vii

Bibliography........................................................................................................................99
Curriculum Vitae ..............................................................................................................113

viii

LIST OF FIGURES
Figure 2.1 Structure of Thimerosal………………………………………………….10
Figure 2.2 Mitogen Activated Protein Kinase (MAPK) Signaling Cascades.……19
Figure 2.3 The Role of JNK in Mitochondrial-Mediated Apoptosis……………….23
Figure 2.4 Components of the AP-1 Transcription Factor………………………..25
Figure 2.5 Sources of Reactive Oxygen Species (ROS)/Reactive Nitrogen
Species (RNS)…………………………………………….…………………………...28
Figure 3.1 Low Passage Growth Curve……………………………………………..33
Figure 3.2 High Passage Growth Curve……………………………………………34
Figure 3.3 Characterization of SK-N-SH Cell Line………………………………...36
Figure 3.4 Determination of JNK Inhibitor II (SP600125) Concentration.…...…..44
Figure 4.1 Thimerosal Induces Cytoskeletal and Membrane Changes………….47
Figure 4.2 LDH Assay………………………………..……….………………………49
Figure 4.3 MTT Assay…………………………………………………………………50
Figure 4.4 DNA Staining Shows Thimerosal-Induced Apoptosis……………...…52
Figure 4.5 Thimerosal Induces Apoptosis…...……...………………………………53
Figure 4.6 Cytochrome c Release Following Thimerosal Treatment…...………..55
Figure 4.7 Caspase 9 Cleavage Following Thimerosal Treatment……………....56
Figure 4.8 Thimerosal Induces Cleavage of Caspase 3……………………..……57
Figure 4.9 Caspase 3 Activity………………………………………………………...59
Figure 4.10 Thimerosal Induces Cleavage of PARP………………………………60
Figure 4.11 Thimerosal Induces Phosphorylation of JNK………………….....…..62
Figure 4.12 Thimerosal Causes Increases in cJun and cFos Levels………….…63
Figure 4.13 Thimerosal Causes Activation of cJun………………………………..65
Figure 4.14 Thimerosal Treatment Increases AP-1 Transcriptional Activation, But
Does Not Involve cFos………………………………………………………………..67
Figure 4.15 Thimerosal Treatment Increases AP-1 Transcriptional Activation
Through cJun……………………………………………………………….………….68
ix

Figure 4.16 JNK Inhibitor II (SP600125) Decreases Markers of Apoptosis……..70
Figure 4.17 SP600125 Has a Protective Effect Following Thimerosal
Treatment……………………………………………………………………………….71
Figure 4.18 TAM67 is Not Protective Following Thimerosal Treatment……..73-74
Figure 4.19 Blocking JNK Activation Decreases HO-1 Levels..……..…………...75
Figure 4.20 TAM67 Does Not Block HO-1 Increase……………………………….77
Figure 4.21 Antioxidant Pretreatment Affects p-JNK Levels Following 5 μM and
10 μM Thimerosal Treatment…………………………………………………. …80-81
Figure 4.22 Antioxidant Pretreatment Affects p-JNK Levels Following 2.5 μM
Thimerosal Treatment…….…………………………………………………….…82-83
Figure 4.23 Antioxidant Pretreatment Affects Bim Levels Following Thimerosal
Treatment……………………………………………………………………….……...84
Figure 5.1 Proposed Pathway of Thimerosal-Induced Neurotoxicity………… …97
Figure 5.2. Time line for Events Following 5 μM Thimerosal Treatment of SK-NSH Cells………………………………………………………………………………...98

x

LIST OF TABLES
Table 1 Thimerosal-Containing Vaccines…………………………………………11

xi

LIST OF SYMBOLS / NOMENCLATURE
AFC – 7-amino-4-trifluoromethyl coumarin
AP-1 – Activator Protein-1
ASK1 – Apoptosis signal-regulating kinase 1
ATP – Adenosine triphosphate
ATF-2 – Activating transcription factor-2
BSA – Bovine serum albumin
CDC – Centers for Disease Control and Prevention
CRE – Cyclic AMP response element
CuZnSOD – Copper,zinc superoxide dismutase
DNA – Deoxyribonucleic acid
DTT – Dithiothreitol
EPA – Environmental Protection Agency
ERK – Extracellular signal-regulated protein kinase
FDA – Food and Drug Administration
GAPDH – Glyceraldehyde-3-phosphate dehydrogenase
GPCR – G-protein coupled receptor
HO-1 – Heme oxygenase-1
IGF-1 – Insulin-like growth factor-1
IOM – Institutes of Medicine
JIP – JNK-interacting proteins
JNK – cJun N-terminal kinase
LDH – Lactate dehydrogenase
MAP2 – Microtubule-associated protein 2
MAPK – Mitogen-activated protein kinase
MAPKK – MAPK kinase
MAPKKK – MAPKK kinase
MEF – Murine embryonic fibroblasts
xii

MeHgCl – Methylmercuric chloride
MEM – Minimum essential medium
MHC – Major histocompatibility complex
MnSOD – Manganese superoxide dismutase
MRNA – Messenger ribonucleic acid
MTT – 3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide
MW – Molecular weight
NAC – N-acetylcysteine
NGF – Nerve growth factor
NOS – Nitric oxide synthase
PARP – Poly(ADP)-ribose polymerase
PBS – Phosphate buffered saline
RNS – Reactive nitrogen species
ROS – Reactive oxygen species
SAPK – Stress-activated protein kinase
SYP – Synaptophysin
TNF-α – Tumor necrosis factor-alpha
TPA – 12-O-tetradecanoylphorbol-13-acetate
TRE – TPA response element
TRX – Thioredoxin
TX – Trolox

xiii

CHAPTER I
Introduction

1.1 Thimerosal and Neurotoxicity
Thimerosal (sodium ethylmercury thiosalicylate, thiomersal, merthiolate) is
an organic mercurial, containing an ethylmercury moiety attached to the sulfur
atom of thiosalicylate.

Since the 1930s, thimerosal has been used in many

products as an antiseptic and a preservative. In recent years, controversy has
surrounded the use of thimerosal in vaccines, as mercury is a known neurotoxin
and nephrotoxin, and can affect other areas of the body as well. Parents began
to be concerned about the possibility that thimerosal could be causing
neurological disorders, particularly autism, because symptoms of autism often
appeared following a round of routine vaccinations.

This concern spurred a

movement among parents, as well as some physicians, to stop vaccinating
children, creating a risk of children acquiring deadly illnesses. The Institutes of
Medicine (IOM), Food and Drug Admnistration (FDA), and Centers for Disease
Control and Prevention (CDC) began to investigate the possibility that thimerosal
was connected to these neurological disorders. In 2001, IOM and FDA issued a
statement that not enough evidence existed to confirm that thimerosal did or did
not cause these disorders, but the possibility did exist.

As a result, it was

recommended that thimerosal be removed from vaccines administered to
children. Since the controversy began in the late 1990s, much of the thimerosal
has been removed from vaccines administered in the United States. However, it
remains in some, such as the influenza vaccine, and is added to multidose vials
used in countries around the world. In a subsequent report issued in May 2004,
1

IOM stated that there is no connection between thimerosal and autism.
However, many parents, physicians, and scientists still believe that a connection
exists between neurodevelopmental disorders and thimerosal. Ongoing studies
will provide valuable information on how this mercurial can affect the brain.
Studies concentrating on thimerosal-induced neurotoxicity are limited, and
exposure guidelines, such as those set by the FDA and Environmental Protection
Agency (EPA), are based on methylmercury studies, which are abundant.
Interestingly, some studies suggest that ethylmercury may react differently than
methylmercury. The current toxicological profile of thimerosal is limited in all
respects, not just concerning its neurotoxic properties. However, with recent
concern about the administration of thimerosal-containing medicinal products to
populations that are vulnerable to neurotoxicity, more studies are necessary to
establish molecular events occurring following thimerosal exposure. In particular,
signaling pathways affected by thimerosal present targets for development of
pharmacological agents that could attenuate toxic effects in patients exposed to
products containing this preservative.
1.2 Hypothesis

It is hypothesized that thimerosal-induced neurotoxicity occurs through a
cJun N-terminal kinase (JNK)/Activator protein-1 (AP-1)-mediated pathway.
1.3 Selection of Neurotoxicity Model
The human SK-N-SH neuroblastoma cell line was chosen as the model for
studying thimerosal-induced neurotoxicity. Neuroblastoma cell lines are routinely
used as models for studying neurotoxicity. The SK-N-SH cell line is a mixed cell
line of neuroblasts and epithelial cells.

This cell line represents the

undifferentiated characteristics of an immature nervous system as would be
2

found in the fetus, neonate, and infant, as opposed to the terminally differentiated
state found in the adult brain.

3

CHAPTER II
Review of Literature

2.1 Mercury

2.1.1 Mercury Exposure

Mercury is both a naturally occurring element and a bi-product of human
activities, particularly industrial emissions, medical uses, and improper disposal
of mercury-containing products. Human exposure to mercury occurs through
three main forms: elemental mercury, inorganic mercury, and organic mercurials.
Elemental mercury includes both the liquid and the vapor forms.

Naturally

occurring elemental mercury can be found in cinnabar ore and can be released
as a gas during volcanic eruptions, while elemental mercury from human
endeavors has numerous sources, including thermometers, barometers, dental
amalgams, and in emissions from coal-burning power plants and medical waste
incinerators. Exposure can occur through direct contact or inhalation of mercury
vapor. Inorganic mercury salts are present in products used by both adults and
children, including skin-lightening creams and germicidal soaps (Counter and
Buchanan,

2004).

ethylmercury,

and

Finally,

organic

phenylmercury.

mercurials
The

most

include
common

methylmercury,
exposure

to

methylmercury occurs through the ingestion of contaminated fish. Exposure to
ethylmercury can occur in the occupational setting and through the use of
medicinal preparations containing thimerosal (Clarkson, 2002).
4

Similarly,

exposure to phenylmercury can occur through the use of medicines, such as
nasal sprays and ophthalmic ointments, containing this compound or through
occupational exposures (http://www.fda.gov/cder/fdama/mercury300.htm).
2.1.2 Mercury Toxicity
Key pieces of information concerning the mechanism of mercury toxicity
have been derived both from cases of patient exposure and from experimental
studies. Symptoms of exposure to each type of mercury have given clues to the
primary targets of toxicity, and experimental studies have confirmed that one of
the primary targets is the brain, along with the kidneys, lungs, skin, eyes, and
immune system. Patients exposed to mercury vapor can experience symptoms
of acute toxicity, which include flu-like symptoms, pulmonary damage, stomatitis,
confusion, lethargy, and vomiting. Acute toxicity has been reported to lead to
fatal acute respiratory distress syndrome (Diner and Brenner, 2004).

Lower

levels of exposure over time can lead to chronic toxicity, which can manifest as
tremors, changes in behavior and mood, and damage to kidneys (Clarkson,
2002). However, both acute and chronic exposure can lead to a variety of other
symptoms, including edema in the hands and feet, shortness of breath, gingivitis,
hallucinations, and the syndrome known as erethism, which consists of
excitability, insomnia, shyness, and loss of memory (Counter and Buchanan,
2004), as well as depression, anorexia, and uncontrolled perspiration (Diner and
Brenner, 2004). Symptoms for exposure to inorganic mercury compounds are
similar to symptoms described for exposure to other forms, and can also include
weakness in extremities, redness of the skin, rash, excessive salivation, and
neuropsychiatric disorders (Counter and Buchanan, 2004).

Methylmercury

exposures can also lead to a wide variety of symptoms. These can include many
of those mentioned above, as well as paresthesia of the mouth, hands, and feet,
which may be due to damage to either the central or peripheral nervous system,
muscle incoordination, constriction of the visual field and deafness (Clarkson et
5

al., 2003; Sanfeliu et al., 2003). In the case of methylmercury toxicity, symptoms
appear following a latent period of a few to several weeks after exposure
(Clarkson et al., 2003). Most studies using phenylmercury compounds are based
on its chemical properties and only a few address its toxicity, so those studies will
not be discussed here.

As mentioned above, ethylmercury exposure occurs

primarily with thimerosal, which will be addressed in detail in the following
section.
Studies to determine the mechanism of mercury toxicity have focused on
both the targets and the molecular events following exposure to the various
mercurials. In workers exposed to the vapor form in the occupational setting,
autopsy samples found that mercury is localized mainly in the brain, kidney, and
lung, with other areas also showing storage, including the testes, thyroid, and
liver (Barregard et al., 1999; Opitz et al., 1996). Studies looking at deposition of
other forms of mercury have found similar distribution, with the primary targets
being the brain and kidney (Friberg and Mottet, 1989; Magos, 2001; Clarkson,
2002; Clarkson et al., 2003; Counter and Buchanan, 2004; Diner and Brenner,
2004). Additionally, studies have indicated that mercurials can cause activation
of the immune system, primarily through hypersensitivity reactions and
autoimmune disorders, and can also cause immunosuppression (Koller, 1973;
Pollard and Hultman, 1997; Moszczynski, 1997; Fournie et al., 2002; Nielsen and
Hultman, 2002; Hansson et al., 2005; Haggqvist et al., 2005; Havarinasab and
Hultman, 2005).
In order to determine the mechanism of damage caused by mercurials,
numerous studies have investigated the molecular events occurring following
exposure to the various types of mercury-containing compounds to which
humans could be exposed.

Studies with mercuric chloride indicate that in a

human leukemic cell line apoptosis occurs through a mitochondrial-dependent
mechanism, including cytochrome c release, caspase 3 activation and
degradation of poly(ADP)-ribose polymerase (PARP; Araragi et al., 2003). Guo
et al. (1998) found that mercuric chloride can also induce apoptosis in human T
6

lymphocytes through production of reactive oxygen species (ROS) and disruption
of mitochondrial function without release of cytochrome c. Additionally, studies
show that inorganic mercury can selectively inhibit one apoptotic pathway (CD95induced apoptosis), while not affecting another (TNF-α-induced apoptosis;
McCabe, Jr et al., 2005). Ben-Ozer et al. (2000) demonstrated that low levels of
mercuric chloride damaged DNA without causing apoptosis in a human cell line
with characteristics of monocytes.

The apoptotic response in these models

indicates a possible mechanism for suppression of the immune system following
mercury exposure, while the selectivity of some of the responses leaves open the
possibility of subsequent immune activation. Studies comparing cell death in
human mononuclear cells treated with either methylmercury chloride (MeHgCl) or
mercuric chloride (HgCl2) found that while both mercurial species induced
apoptosis, each affected the cells in a different way.

Both species affected

mitochondrial function, but HgCl2 did not cause release of cytochrome c and
caused an increase in anti-apoptotic Bcl-2. On the contrary, MeHgCl did cause
release of cytochrome c and no increase in Bcl-2. Additionally, both forms of
mercury were able to activate the caspase cascade, as seen by cleavage of the
caspase 3 substrate PARP (Shenker et al., 2000). In studies with cultured rat
astrocytes, Brawer et al. (1998) found that mercuric chloride can increase ROS
and can induce a stress response in these cells, including an increase in mRNA
levels of heme oxygenase-1 (HO-1).
Numerous studies have been conducted with methylmercury since it is
one of the greatest exposure risks to humans.

Because one of the primary

concerns is neurotoxicity following methylmercury exposure, many studies have
focused on damage to the brain and the mechanism of that toxicity. One of the
main concerns with methylmercury exposure is the risk to the developing fetus.
Methylmercury can cross both the placenta and the blood-brain barrier (Mansour
et al., 1973,1974; Aschner and Aschner, 1990; Kakita et al., 2000), allowing for
significant damage to the developing fetus, leading to motor, sensory, and mental
impairment, as well as neuropsychological disorders (Clarkson, 2002; Clarkson
7

et al., 2003; Sanfeliu et al., 2003; Counter and Buchanan, 2004). Additionally,
studies have reported that methylmercury, as well as ethylmercury, can undergo
biotransformation to inorganic mercury once inside cells, possibly causing further
damage (Norseth and Clarkson, 1970; Vahter et al., 1994; Blair et al., 1975;
Suda et al., 1992), although the contribution of the inorganic mercury to
subsequent damage has yet to be determined.
Further studies examining the mechanism of methylmercury-induced
toxicity have involved determining the molecular events following exposure.
Again, as with other reports, many of these studies have concentrated on
damage to immune system components and to the brain. Shenker et al. (1998,
1999, 2000) found that methylmercury causes a decline in mitochondrial function,
subsequent generation of ROS, and, ultimately, apoptosis in human T-cells.
Many other studies have implicated the production of ROS in cellular damage
following methylmercury exposure, many of which demonstrate the protective
effect of antioxidants (Ali et al., 1992; Sarafian et al., 1994; Choi et al., 1996;
Sorg et al., 1998; Sanfeliu et al., 2001). Cerebellar neurons, a main target for
mercurials, also underwent apoptosis following methylmercury treatment
(Kunimoto, 1994; Nagashima et al., 1996). Allen et al. (2001) demonstrated that
methylmercury selectively targets the mitochondria of cultured astrocytes,
another target for mercurials.

Additional studies with HeLa cells have

demonstrated that both methylmercury and ethylmercury inhibit DNA and RNA
synthesis (Chao et al., 1984), which could be another mechanism by which
mercurials induce cellular damage and death. Methylmercury has also been
shown to block microtubule polymerization, which causes a significant effect on
cell division and migration during development (Sanfeliu et al., 2003). Taken
together, these studies indicate that mercurials may act through a variety of
pathways, including increasing ROS, activating apoptosis-inducing signaling
pathways and causing direct injury to cellular components, to cause cell damage
and death.
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2.2 Thimerosal

2.2.1 Background
Thimerosal,

also

known

as

thiomersal,

merthiolate,

or

sodium

ethylmercurithiosalicylate, consists of an ethylmercury moiety attached to the
sulfur atom of thiosalicylate (Figure 2.1). The sulfur-mercury attachment point is
the reactive site of the molecule, allowing for reactions with sulfhydryl groups of
cellular components, including glutathione, enzymes, and structural proteins.
Thimerosal is both water-soluble and lipophilic, able to cross cellular membranes
as a free acid (Elferink, 1999).

2.2.2 Usage
Thimerosal has antifungal and antibacterial properties and has been used
extensively as an antiseptic and a preservative since the 1930s. Thimerosal is still
used in a variety of medicinal products, including nasal sprays, antibiotic eye and
ear drops, antifungal creams/lotions, and a multitude of ophthalmic solutions
(http://www.fda.gov/cder/fdama/mercury300.htm).

Most notably, thimerosal is

used in numerous vaccines available in the United States (Table 1;
http://www.fda.gov/cber/vaccine/thimerosal.htm), as well as in vaccines and other
medicinal products used around the world. In the late 1990s, controversy began to
surround this usage, particularly in vaccines and other medicinal products that
were administered to neonates, infants, children, and pregnant women. Several
vaccines have been added to the childhood vaccination schedule, and in some
cases the cumulative dose of mercury a child received was exceeding the daily
amount allowed by EPA guidelines (0.1 μg/kg/day; Ball et al., 2001; Clements et
9

al., 2001).

Subsequently, thimerosal has been removed from most pediatric

vaccines in the United States, with the exception being the influenza vaccine

Thiosalicylate

Ethylmercury

Figure 2.1. Structure of thimerosal. Thimerosal
consists of ethylmercury attached to the sulfur atom
of thiosalicylate. This sulfur-mercury attachment
point is also the reactive sight of the molecule.
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THIMEROSAL-CONTAINING VACCINES
AVAILABLE IN THE UNITED STATES

Vaccine (Tradename)

Thimerosal Content

DTaP (Tripedia)

≤ 0.3 μg Hg/0.5 mL dose

DTaP-HepB-IPV (Pediarix)

<0.0125 μg Hg/0.5 mL dose

DT (No trade name)-single dose

<0.3 μg Hg/0.5 mL dose

DT (No trade name)-multidose

0.01% (25 μg Hg/0.5 mL dose)

Hepatitis B (Engerix B)

< 0.5 μg Hg/0.5 mL dose

Hepatitis B (Recombivax HB)-adult

25 μg Hg/0.5 mL dose

Hep A/Hep B (Twinrix)

< 1 μg Hg/1.0 mL dose)

Influenza (Fluzone)

0.01% (12.5 μg Hg/0.25 mL dose)
0.01% (25 μg Hg/0.5 mL dose)

Influenza (Fluzone Preservative Free)

≤ 0.5 μg Hg/0.25 mL dose
≤ 1.0 μg Hg/0.5 mL dose

Influenza (Fluvirin)

0.01% (25 μg Hg/0.5 mL dose)

Influenza (Fluvirin Preservative Free)

<1.0 μg Hg/0.5 mL dose

Japanese Encephalitis (JE-VAX)

35 μg Hg/1.0 mL dose
17.5 μg Hg/0.5 mL dose)

Meningicoccal (Menomune A, C, AC
and A/C/Y/W-135-mulitdose

0.01% (25 μg Hg/0.5 mL dose)

Td (No trade name)

8.3 μg Hg/0.5 mL dose

Td (Decavec)

0.3 μg Hg/0.5 mL dose

TT (No trade name)

0.01% (25 μg Hg/0.5 mL dose)

Table 1.

Thimerosal-containing vaccines.

Many vaccines still contain

thimerosal. However, thimerosal-free options are available for children. DtaP=
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine; DT= Diphtheria &
Tetanus Toxoids; HepB=Hepatitis B; IPV= Inactivated Poliovirus Vaccine;
HepA=Hepatitis A; Td= Tetanus & Diphtheria Toxoids; TT= Tetanus Toxoid.
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(Table 1), which is recommended for children ages 6 months and older, as well as
pregnant women. Furthermore, medicinal products used in developing nations still
contain thimerosal and are given to children of all ages, as well as pregnant
women (Clements et al., 2001).
2.2.3 Symptoms of Toxicity
Symptoms of ethylmercury toxicity have been established through cases of
patient exposures from occupational, dietary, and medicinal sources. According to
Magos (2001) blood mercury levels approaching or exceeding 1 μg/mL
corresponded with symptoms of toxicity, with levels above 15 μg/mL of mercury
resulting in several fatal cases. In these cases of toxicity, symptoms did not occur
until weeks after exposure. One of the most common symptoms of ethylmercury
toxicity was constriction of the visual field. Patient symptoms varied, and included,
but were not limited to, symptoms similar to mercury vapor exposure, with
additional symptoms of paresthesia, which may be due to lesions of the central or
peripheral nervous system, hypoesthesia, disturbance of speech, hearing loss,
incoordinate muscle activity, muscle weakness and spasticity, tremor, confusion,
and delirium.

In cases of injection of large amounts of thimerosal, necrosis

occurred at the injection site (Magos, 2001).
An additional problem with thimerosal, as with other mercurials, is the effect
on the immune system. Allergic contact dermatitis is a common reaction following
exposure to thimerosal, with most cases involving a localized reaction. However,
Lee-Wong et al. (2005) present a case study of a patient that developed systemic
contact dermatitis. Following sensitization with thimerosal-containing contact lens
solution, the patient developed a T-cell-mediated reaction after receiving an
influenza vaccine, leading to a maculopapular rash on all four extremities and the
torso.
2.2.4 Toxicity Studies-Cell Culture
12

As with other mercurials, thimerosal appears to elicit effects on a variety of
cells types, thus accounting for the toxic symptoms observed in a variety of organ
systems. One of the effects of thimerosal that has been studied most extensively
is calcium alterations. Thimerosal caused increases in intracellular calcium in rat
thymus lymphocytes, and these changes were dependent on the influx of
extracellular calcium (Martin et al., 1991).

Thimerosal also caused similar

changes in human umbilical cord vein endothelial cells by increasing the influx of
extracellular calcium and by releasing intracellular stores. This study indicates a
possible mechanism by which thimerosal increases levels of nitric oxide and
prostacyclin, and thus cause vasodilation (Gericke et al., 1993). Similar changes
in intracellular calcium caused by the synergistic effects of thimerosal and Nformyl-methionyl-leucyl-phenylalanine
leukotrienes

following

the

led

liberation

to
of

the

increased

arachidonic

acid

formation
in

of

human

polymorphonuclear white blood cells (Hatzelmann et al., 1990). Rat cerebellar
neurons treated with thimerosal also showed increases in intracellular calcium
levels (Ueha-Ishibashi et al., 2004a). Changes in calcium levels can lead to a
variety of outcomes, including apoptosis, and could be a possible mechanism
through which thimerosal causes damage to cells.

Chao et al. (1984)

demonstrated that ethylmercuric chloride inhibited both DNA and RNA synthesis
in HeLa cells, which could also lead to apoptosis.
Another event associated with cellular damage is an increase in reactive
oxygen species. HeLa S cells treated with thimerosal showed activation of focal
adhesion kinase and cytoskeletal changes, both of which were attributed to the
production of ROS (Kim et al., 2002). Furthermore, decreased glutathione levels
were seen in rat cerebellar neurons (Ueha-Ishibashi et al., 2005), rat thymocytes
(Ueha-Ishibashi et al., 2004b), Jurkat T cells (Makani et al., 2002), cultured
neuroblastoma cells (SH-SY5Y) and glioblastoma cells (James et al., 2005). An
increase in ROS and subsequent decrease and possible depletion of glutathione
could lead to cellular damage and apoptosis, as was shown by Makani et al.,
(2002).

Debbasch et al. (2001) also found an increase in ROS in a human
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conjunctival cell line treated with thimerosal. Baskin et al. (2003) found evidence
that cultured human neurons and fibroblasts undergo apoptosis following
thimerosal treatment. Researchers demonstrated that thimerosal exposure at
micromolar concentrations led to membrane damage, along with apoptotic cell
death as shown by DNA condensation and fragmentation, caspase 3 activation,
and the presence of apoptotic bodies. Micromolar concentrations of thimerosal
also caused changes in mitochondrial membrane potential, increases in ROS,
and translocation of pro-apoptotic Bax to the outer mitochondrial membrane,
while at the same time showing no changes in levels of Bax or Bcl-2 in a
neuroblastoma cell line (Yel et al., 2005).
To begin to address the question of the effects of thimerosal on the
development of the brain, Parran et al. (2005) used SHSY5Y neuroblastoma
cells to determine if thimerosal exposure affected nerve growth factor (NGF)
signaling. They found that neuroblastoma cells exposed to thimerosal and NGF
showed decreased phosphorylation, and thus decreased activation, of the NGF
receptor and mitogen-activated protein kinases (MAPK), indicating that
neurotropin signaling may be a target for thimerosal in the developing brain.
SHSY5Y cells treated with thimerosal had decreased methionine synthase
activity and corresponding blocks in stimulatory effects of dopamine and insulinlike growth factor-1 (IGF-1). These results indicate that thimerosal may interfere
with D4 dopamine receptor-mediated phospholipid methylation as well as DNA
methylation, which has been linked to attention deficit disorder (Waly et al.,
2004). In the first study to identify that thimerosal also caused mitochondrialmediated apoptosis, our lab showed the release of cytochrome c, activation of
caspases 9 and 3, and degradation of PARP in SK-N-SH neuroblastoma cells
(Humphrey et al., 2005).
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2.2.5 Toxicity Studies-Animal Studies
Studies are limited using animal models to examine the toxic effects of
thimerosal. Blair et al. (1975) found that squirrel monkeys that were given high
doses of thimerosal intranasally for six months showed no signs of toxicity, as
determined by changes in weight and food consumption, changes in hematologic
parameters and blood chemistry, as well as organ damage.

However, they

accumulated significant levels of mercury, mostly in the inorganic form, in the
brain, liver, kidney, and muscle.

Although the animals showed no signs of

toxicity, the accumulation of mercury in the brain is of concern to humans, as it
poses a potential health risk. Gasset et al. (1975) found similar results in studies
using albino New Zealand rabbits. When thimerosal was applied either topically
to the eye or subcutaneously, mercury was present in the blood, brain, liver, and
kidney. Oral thimerosal administration to A.SW mice led to accumulation of both
ethylmercury and Hg2+ in kidney, liver, and mesenterial lymph nodes
(Qvarnstrom et al., 2003).

CD1 mice given a single injection of thimerosal

showed mercury present in the blood, brain, kidney, and muscle tissue, and
levels in the brain, though not as high as other tissues, remained elevated after 7
days (Harry et al., 2004). Results on infant monkeys (Macaca fascicularis) found
similar results.

Researchers found that infant monkeys that received

intramuscular injections of thimerosal showed increases in inorganic mercury
levels in the brain, and the average level did not decrease by 28 days, which
corresponds to the significantly longer half-life of inorganic mercury (Burbacher et
al., 2005). Importantly, studies have indicated that genetic susceptibility may
play a role in sensitivity to thimerosal-induced toxicity.

Studies comparing

different mouse strains (SJL/J, C57BL6/J, BALB/cJ) found that the SJL/J
autoimmune-sensitive strain was more susceptible to toxicity than the other
strains, indicating that perhaps there is a genetic predisposition to thimerosal
sensitivity (Hornig et al., 2004).

In studying the immunosuppressive and

autoimmune effects of thimerosal on a variety of mouse strains, Havarinasab et
al. (2004, 2005) found similar genetic susceptibility to thimerosal based on major
15

histocompatibility complex (MHC) haplotypes.

Additionally, they found that

thimerosal causes an initial immunosuppression, but by two weeks, thimerosal
caused an extensive autoimmune response.
2.2.6 Toxicity Studies-Human
Few toxicity studies have been conducted to look at human exposure to
thimerosal. Pichichero et al. (2002) studied infants following administration of
thimerosal-containing vaccines.

They measured levels of mercury in blood,

urine, and stool samples 3-28 days after vaccination, and found that blood and
urine mercury levels were low at the time point measured, but levels were high in
stools, indicating that the primary route of elimination is through the stools.
Stajich et al. (2000) measured mercury levels in both term and preterm infants 48
to 72 hr after receiving one dose thimerosal-containing Hepatitis B vaccine
(contained 12.5 μg mercury) during the first week of life. They found that both
groups of infants had significantly increased post-vaccination blood mercury
levels, and the preterm infants had higher mean mercury level than the term
infants.

These higher levels may be due to the relatively higher amount of

mercury received by the lower birth weight infants, as well as to the possibility
that the preterm infants may not be able to eliminate the mercury as effectively
as the term infants.
2.2.7 Comparison of Ethylmercury and Methylmercury
Organizations that set guidelines for exposure to ethylmercury have based
the safe levels on studies with methylmercury and have assumed that the two
forms of mercury have similar toxicities. Therefore, studies that compare the
effects of methylmercury and ethylmercury are important and necessary to
determine if safety guidelines are correctly estimating the relative toxicities of
both compounds.

Studies using ethylmercuric chloride and methylmercuric

chloride administered to Porton Wistar rats demonstrated that ethylmercury
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caused a larger weight loss and greater amounts of total and organic mercury in
the blood than methylmercury. Methylmercury caused higher levels of total and
organic mercury in the brain and kidneys, as well as more severe coordination
disorders. However, ethylmercury specifically affected the telencephalon and
diencephalon, with mercury deposits visible upon staining, while methylmercury
did not deposit in these areas.

Additionally, ethylmercury caused more

widespread damage to the kidneys than methylmercury, which showed higher
levels of mercury deposition. This discrepancy was attributed to the fact that in
ethylmercury-exposed kidneys the damage was so significant that large amounts
of mercury deposits may have been lost as damaged cells were sloughed off.
Finally, by increasing the ethylmercury dose by 20%, many of these parameters
increased equal to or above the levels seen in methylmercury. For instance, the
increase in ethylmercury caused increased levels of coordination disorders that
were equal to or higher that methylmercury-treated rats (Magos et al., 1985).
Other basic differences have also been discovered.

The half-life of

methylmercury has been estimated to be about 50 days, while the half-life of
ethylmercury has been estimated to be only about 7 days (Pichichero et al.,
2002; Counter and Buchanan, 2004). Methylmercury is actively transported into
the brain by an amino acid transporter, while thimerosal crosses membranes in
the free acid form (Elferink, 1999; Counter and Buchanan, 2004), but both have
been shown to accumulate in the brain and to be converted to inorganic mercury.
However, ethylmercury is converted to inorganic mercury at a much higher rate
than methylmercury (Clarkson, 2003). On the other hand, some similarities have
also been found. Both readily bind to sulfhydryl groups, and excretion of both
forms occurs mainly through the fecal route. Additionally, both compounds have
similar distribution patterns in the body.

Finally, following exposure to either

compound, there is a latent period before symptoms of toxicity appear (Magos,
2001; Clarkson, 2003; Counter and Buchanan, 2004). Therefore, despite some
similarities, methylmercury and ethylmercury exhibit enough differences that they
should be considered separately when determining the potential for toxicity.
17

2.3 cJun N-Terminal Kinase (JNK)/Activator Protein-1 (AP-1)

2.3.1 Background-JNK
Mitogen-activated protein kinases (MAPK) play an important regulatory
role in a variety of cellular processes, including growth, differentiation, cellular
migration, and apoptotic cell death. Three groups of MAPKs (p38, JNK, and
ERK) have been identified in mammals (Figure 2.2), each of which is the terminal
kinase in a protein kinase cascade (Davis, 2000). Overall the MAPK cascades
can be activated by a variety of physical and chemical stimuli, including growth
factors, cytokines, environmental insults, heat, ROS, and changes in pH and
osmolarity (Karin and Gallagher, 2005; Sumbayev and Yasinska, 2005). The
cJun N-terminal kinase (JNK), also known as stress-activated protein kinase
(SAPK), is a serine/threonine kinase that is activated by environmental stresses
and is of particular interest in relation to signaling responses following the
genotoxic insult of thimerosal. The JNK family of protein kinases consists of
three JNK genes, which produce 10 JNK isoforms. All 10 JNK isoforms are
either 46 kDa or 54 kDa molecular weight (MW). JNK1 and JNK2 genes are
expressed ubiquitously, while JNK3 is expressed mostly in the brain, but also in
the heart and testis (Kuan et al., 1999; Davis, 2000).
2.3.2 Activation and Inactivation
The JNK MAPKs are activated by phosphorylation of the ThreonineProline-Tyrosine (Thr-Pro-Tyr) motif by an upstream MAPK kinase. MKK4 and
MKK7 specifically phosphorylate JNKs. MKK4 and MKK7 isoforms are activated
by upstream MAPKK kinases (MAPKKK). The MAPK kinases (MAPKK) both
dually phosphorylate JNKs on Thr and Tyr, MKK7 preferentially phosphorylates
on Thr and MKK4 on Tyr, indicating that while they can work individually, the
18

MAPK Signaling Cascades
Stress, Growth Factors, Cytokines, Mitogens,
G Protein Coupled Receptors (GPCR)

MAPKKK

MAPKKK

MAPKKK

MEK1/2/5

MKK4/7

MKK3/6

ERK

JNK

p38

Apoptosis, Development,
Differentiation, Growth,
Inflammation
Figure 2.2. MAPK Signaling Cascades. Following exposure to a
stimulant, any of a variety of MAPKKKs can be activated, depending on
the stimuli, and can phosphorylate downstream MAPKK, which, in turn,
phosphorylate MAPK (ERK, JNK, or p38). The terminal MAPK in the
cascade can then proceed to phosphorylate other cellular components,
such as transcription factors, leading to a biological response.
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MAPKKs may also work together to activate JNK. Additionally, MKK7 and MKK4
are primarily activated by cytokines and environmental insults, respectively. Both
MAPKKs are present in the nucleus and the cytoplasm; therefore, JNKs can be
activated in both locations. The MAPKKKs that activate MAPKK upstream of
JNKs include MEKK1 through 4, ASK1 and 2, TAK1, TPL2, and members of the
mixed-lineage protein kinase group. JNK may be activated either transiently or in
a sustained manner, which could determine the outcome of JNK signaling (Davis,
2000). Differential activation of JNK isoforms, as well as activation of upstream
MKKs, has been shown to depend on both cell type and the particular cellular
stress (Butterfield et al., 1999; Mielke et al., 2000). Activation of specific JNK
genes, as well as activation of specific downstream substrates, was also shown
to occur in response to growth and differentiation signals (Behrens et al., 1999).
In addition, scaffolding molecules, such as the JNK-interacting proteins (JIP),
may potentiate JNK signaling, although the exact mechanism has not been
elucidated.

Inactivation

of

JNK

protein

kinases

occurs

through

dephosphorylation by phosphatases (Davis, 2000).
2.3.3 Function
Activated JNK isoforms can proceed to phosphorylate other cellular
proteins, including transcription factors. JNK has been shown to phosphorylate
c-Jun, activating transcription factor-2 (ATF2), Elk-1, c-Myc, p53, 14-3-3, Bcl-2,
Smac, and Bim (Brichese et al., 2004; Tsuruta et al., 2004; Karin and Gallagher,
2005).
JNK is activated by cellular stress and may play a role in either apoptosis
or survival. JNK has been shown to be essential to apoptosis (Morishima et al.,
2001; Kuan et al., 1999; Tournier et al., 2000), and, more specifically, the JNK3
gene has been shown to be involved in neuronal apoptosis (Yang et al., 1997).
The targets for JNK in apoptosis are still being elucidated.

While several

candidates have emerged, their roles in JNK-induced apoptosis are unclear, and,
in some cases, these targets do not appear to be essential to the signaling
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pathway even though they are involved. This is the case for p53 and c-Myc
(Davis, 2000). Studies with murine embryo fibroblasts (MEF) from Jnk1-/- Jnk2-/embryos indicate that JNK activity is required for mitochondrial-mediated, but not
caspase-8-mediated, apoptosis in response to UV radiation. JNK was required
for release of cytochrome c, which combines with Apaf-1, ATP, and procaspase9, leading to the activation of caspase-9 and caspase-3 (Tournier et al., 2000;
Figure 2.3). However, the exact role of JNK in this pathway is unknown, as all
intermediates have not been determined. Similar activation of JNK has been
established in response to cadmium in neuronal apoptosis, including the
involvement of cJun and caspase 3 (Kim et al., 2005b). One mechanism through
which JNK may be acting is phosphorylation of either proapoptotic or
antiapoptotic proteins or both.

One such proapoptotic protein that JNK can

phosphorylate is Bim. Activation of Bim through phosphorylation allows Bim to
contribute to apoptosis by interaction with other Bcl-2 proteins (Becker et al.,
2004; Harris and Johnson, 2001; Lei and Davis, 2003; Okuno et al., 2004;
Putcha et al., 2003). Under normal conditions, Bim is attached to LC8 in the
dynein motor complex, but translocates to the mitochondrial membrane when
activated, wherein Bim interacts with Bax/Bad, causing pore formation and
cytochrome c release, ultimately leading to apoptosis. When released from the
microtubules, Bim can also interact with and neutralize antiapoptotic Bcl-2
proteins, which also leads to apoptosis (Mollinedo and Gajate, 2003). According
to Putcha et al., (2001) this Bim-mediated apoptosis is specific to neuronal cells,
and does not occur in non-neuronal cells in the brain.
Less information is known about the role JNK may play in survival
signaling. This role may be related to a transient activation of JNK, as opposed
to the sustained activation that occurs during apoptosis. JNK is only transiently
activated in response to cytokines, and apoptosis does not occur (Davis, 2000).
Evidence for this hypothesis of JNK survival signaling was found in studies of
JNK1-/-JNK2-/- embryos that had increased apoptosis in the forebrain, while at the
same time these embryos had reduced apoptosis in the hindbrain, indicating that
21

JNK-mediated survival and apoptosis signaling may both be essential to brain
development (Kuan et al., 1999; Sabapathy et al., 1999).
JNK may also be involved in tumor development, albeit the exact role is
still unclear. One hypothesis is that JNK-induced apoptosis may be inhibited in
some manner. Since JNK1 and JNK2 are ubiquitously expressed, this inhibition
may occur through either proteins that directly inhibit JNK activation or through
inhibition of proteins that activate JNK. Targets of JNK pro-apoptotic signaling
may also be altered and can no longer respond as they would in normal cells
(Davis, 2000).
JNK also functions in embryonic development, but many more studies will
be necessary to determine its exact role. Studies using embryos possessing
JNK gene mutations have demonstrated that the complement of JNK genes are
essential to embryonic viability, and JNK survival and apoptotic signaling appear
to be necessary for normal embryonic development (Kuan et al., 1999).
2.3.4 Background-AP-1
Many biological responses attributed to the JNK pathway are mediated
through activation of the Activator Protein-1 (AP-1) transcription factors. The AP1 transcription factors are protein dimers composed of members of the Jun
(cJun, JunB, JunD), Fos (cFos, FosB, Fra1, Fra2), Maf (cMaf, MafB, Maf G/F/K,
Nrl), or ATF (ATF2, LRF1/ATF3, B-ATF, JDP1, JDP2) families, with cJun and
cFos being the most studied. The proteins form dimers through interactions of
leucine zipper regions (Figure 2.4).

Members of the Jun family can form

homodimers, or may form heterodimers with members of other families, most
notably cFos. AP-1 is activated by similar stimuli as mentioned above for the
JNK signaling pathway. In response to stress, growth factors, or a variety of
other signals, the JNK MAPK cascade is activated, and subsequently activates
the AP-1 transcription factor by translocating to the nucleus and phosphorylating
distinct residues on the dimer.
the

The AP-1 dimer recognizes and binds to either

12-O-tetradecanoylphorbol-13-acetate
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Figure 2.3.
The role of JNK in mitochondrial-mediated
apoptosis. JNK activation has been shown to be essential to
mitochondrial-mediated, stress-induced apoptosis. However, the
exact targets for JNK have not been established.
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TGAG/CTCA-3’) or the cAMP response elements (5’-TGACGTCA-3’) via a basic
DNA binding domain, wherein the transcription factor proceeds to alter
transcription of the target gene. The target gene in question depends upon the
original stimuli as well as the components of the dimer. Therefore, the regulation
and outcomes of AP-1 activity are extremely complex due to the large number of
influential factors and are still being studied extensively.
AP-1 transcription factors have been shown to be involved in cellular
proliferation, survival, and apoptosis.

As stated above, AP-1 is activated by

growth factors, and numerous studies have shown that altering jun or fos affects
cellular proliferation, both in cell culture and in animal models (Tong et al., 1998).
For instance, overexpression of cFos and cJun proteins can lead to
immortalization and transformation in both chicken and mouse embryo
fibroblasts, respectively. Additionally, transgenic mice with either c-fos-/- or a
dominant negative cJun do not respond to tumor promoters, displaying a
resistance to malignancy (Shaulian and Karin, 2001).
On the other hand, AP-1 can also mediate apoptosis, as when activated
by genotoxic stress, such as UV radiation or alkylating agents. In neuronal cells,
phosphorylation of cJun by JNK has been shown to be essential to the induction
of AP-1-mediated apoptosis. In addition, c-fos-/- mice have been shown to be
resistant to apoptosis in retinal photoreceptors. Numerous other gene knockout
studies have shown that knockout of cjun can confer resistance to apoptosis.
Further evidence for AP-1 mediated apoptosis has emerged through the
discovery of proapoptotic target genes, including FasL and Bim (Shaulian and
Karin, 2002). As a result of the complexity of AP-1 induction and regulation, the
outcomes of AP-1 transcription factor activation are diverse.

2.3.5 Outcomes
JNK signaling has been implicated in various disease processes.
Morishima et al. (2001) found that β-amyloid, when applied to cortical neurons,
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Figure 2.4 Components of the AP-1 transcription factor. The
AP-1 transcription factor is a dimer composed of members of the
Jun and Fos families, as well as members of the Maf and ATF
families. The individual components form dimers through a leucine
zipper dimerization domain, and bind DNA through a basic DNAbinding region. AP-1 transcription factors can bind to the TRE or
CRE response elements.
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activated JNK signaling, indicating a possible mechanism of neuronal cell damage
in patients with Alzheimer’s disease. Additionally, increases in immunoreactivity of
cJun have been reported in apoptotic neurons in Alzheimer’s Disease (Anderson
et al., 1996).

Zhang et al., (2003) found that JNK may mediate apoptosis in

eosinophils, and the activation or inactivation of JNK signaling in response to
cytokines may play a role in allergic responses. JNK2 has been implicated in the
formation of atherosclerotic lesions (Ricci et al., 2004). Finally, studies with rats
have shown that aging animals have increases in constitutive levels of cjun and
cfos mRNA, indicating that the AP-1 complex may play a role in the aging process
(Tong et al., 1998).
Because JNK signaling is essential to apoptosis in many cell types, and in
particular in response to cellular stress, JNK signaling may be a beneficial target
in disease management in either preventing inappropriate apoptosis or through
induction of apoptosis in cancer cells.

Studies have begun to look at this

possibility. Jurkat leukemia cells underwent JNK-induced apoptosis in response
to the drug pramanicin (Kutuk et al., 2005). Zhang et al. (2003) suggested that
by inducing JNK-mediated apoptosis, inflammation resulting from eosinophilia
may be reduced in asthma and other allergic diseases.

Studies with rodent

models of rheumatoid arthritis have shown that using the JNK inhibitor SP600125
will

prevent

joint

destruction

by

blocking

the

induction

of

matrix

metalloproteinases, as well as possibly reducing the inflammatory response
(Karin and Gallagher, 2005). In the end, extensive studies will be required to
determine if targeting JNK activity will be beneficial in treating diseases, because
it is believed that blocking the detrimental effects of JNK will have the negative
effect of also blocking the beneficial effects. For instance, could blocking JNKinduced apoptosis in the heart also result in the loss of JNK-mediated
cardioprotective effects, only resulting in a different type of disease process?
Similar problems must also be addressed concerning the targeting of AP-1.
Future studies in animal models could answer some of these questions and lead
to the development of pharmacological agents that could ameliorate JNK26

mediated disease processes in humans.

So far, studies have not been

successful in targeting JNK-induced inflammation in patients with Crohn’s
disease (Waetzig and Herdegen, 2005).
2.4 Oxidative Stress

2.4.1 Background
Basal levels of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) are produced in all cell types by a variety of reactions (Figure 2.5).
Endogenous antioxidants are involved in the removal of free radicals to alleviate
potential damage. Overproduction of free radicals due to disease processes or
injury can lead to oxidation of proteins, lipids, and nucleic acids. Subsequent
cellular damage, including apoptotic cell death, has been linked to neurotoxicity.
Additionally, the overproduction of free radicals can deplete endogenous
antioxidants, causing more oxidative damage because the cell no longer has the
capacity to remove free radicals (Lewen et al., 2000).

2.4.2 Sources of ROS/RNS
Many pathways in the brain result in the generation of free radicals (Figure 2.5).
The major site of free radical production in the cell is the mitochondria via the
electron transport chain. During the production of adenosine triphosphate (ATP),
the reducing equivalents (e-, H+, NADH, FADH2) are passed along the enzymes
of the electron transport chain.

Under basal conditions, about 1-2% of the

oxygen processed by the mitochondria is converted to superoxide (O2.-).
However, disturbance of these mitochondrial enzymes, such as cytochrome c,
due to injury or disease, can result in increased production of free radicals
because electrons will be increasingly transferred to oxygen. Increased Ca2+
influx can also lead to increased ROS through a similar process of enzymatic
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Figure 2.5. Sources of ROS/RNS. Several pathways result in
free radical production in the cell. Overproduction of ROS/RNS can
exhaust endogenous antioxidants, leading to lipid peroxidation,
protein oxidation, and DNA/RNA oxidation. This cellular damage
can ultimately lead to apoptotic cell death. L-arg=L-arginine;
G2;
NOS=nitric
oxide
synthase.
PGG2=prostaglandin
XDH=xanthine dehydrogenase; XO=xanthine oxidase.
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disruption due to calcium-induced alterations in the inner mitochondrial
membrane (Lewen et al., 2000; Chinopoulos and Adam-Vizi, 2006).
A variety of sources of ROS/RNS exist outside the mitochondria. One
source of ROS is the phospholipase A2-cyclooxygenase pathway, which can lead
to the production of superoxide in neurons, glia, microglia, and endothelial cells.
Increases in intracellular Ca2+ can lead to the activation of nitric oxide synthase
(NOS), leading to the production of nitric oxide (NO.), which can further react with
superoxide to form peroxynitrite (ONOO-) in most cell types. The conversion of
xanthine dehydrogenase to xanthine oxidase can result in the formation of
hydrogen peroxide (H2O2) in the endothelium.
these

free

radicals

by

endogenous

Without sufficient removal of

antioxidants,

including

glutathione,

manganese superoxide dismutase (MnSOD), copper zinc superoxide dismutase
(CuZnSOD), catalase, ascorbic acid, and vitamin E, ROS and RNS can cause
cellular damage through lipid peroxidation, protein oxidation, and DNA/RNA
oxidation (Lewen et al., 2000).

2.4.3 Outcomes
Oxidative stress has been linked to apoptosis in the brain following a
variety of insults.
mitochondria.

A key event is the release of cytochrome c from the

This loss leads to further production of ROS because of the

disruption of the electron transport chain.

Cytochrome c interacts with other

proapoptotic factors, including initiator caspase 9, Apaf-1, and ATP, which leads
to the cleavage and activation of the effector caspase 3.

Active caspase 3

proceeds to cleave products such as PARP, which when cleaved can no longer
repair DNA.

Caspase 3 also activates nucleases that are involved in the

cleavage of DNA during apoptosis. In addition, cytosolic increases in ROS/RNS
can activate proapoptotic factors in the cytoplasm, such as caspase 8, Bax, and
Bid (Lewen et al., 2000). Oxidative stress and the subsequent cellular damage
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can also activate various signaling pathways that may or may not be involved in
apoptosis (Leonard et al., 2004; Valencia and Moran, 2004).
Metals, such as mercury, have been implicated in the production of ROS
(Leonard et al., 2004). The most important free radical-generating reactions are
the Fenton-type reaction and the Haber-Weiss reaction. The Fenton reaction
involves the reaction of a transition metal with H2O2 to form the highly reactive
hydroxyl radical (.OH) and an oxidized metal ion. In the Haber-Weiss reaction,
an oxidized metal and superoxide (O2.-) react to form a reduced metal ion and
O2, which then react with H2O2 to form .OH. The resultant free radicals can
cause metal-induced diseases, including cancer (Leonard et al., 2004). ROS
have been implicated in methylmercury-induced neurotoxicity (Ali et al., 1992).
One of the signaling pathways activated by both free radicals and metals
is the JNK signaling pathway. H2O2 has been shown to activate MAPK pathways
directly, but also to inhibit phosphatases, which would lead to prolonged
phosphorylation of MAPK signaling components (Leonard et al., 2004; Pham et
al., 2005). One mechanism through which oxidative stress may activate JNK
directly is through the activation of apoptosis signal-regulating kinase 1 (ASK1),
which is a MAPKKK. ASK1 is normally complexed with thioredoxin (Trx) in the
cytoplasm and in the mitochondria.

Trx is redox sensitive, and when Trx is

oxidized, it releases ASK1, thus activating the enzyme, which can then activate
downstream MAPKK, leading ultimately to apoptosis (Sumbayev and Yasinska,
2005).
AP-1 activity is also stimulated by oxidative stress, including H2O2 and
superoxide. Although the exact mechanism through which free radicals activate
AP-1 has not been elucidated, the activation may be mediated through
phosphorylation (Meyer et al., 1994; Tong et al., 1998; Leonard et al., 2004) or
through redox-sensitive cysteine residues (Sun and Oberley, 1996).
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CHAPTER III
Methods
3.1 Cell Line

A human neuroblastoma cell line (SK-N-SH) obtained from American Type
Culture Collection (HTB-11) was maintained in minimum essential medium
(MEM) supplemented with 10% heat-inactivated fetal bovine serum, 1%
antibiotics (penicillin/streptomycin/neomycin), 1% non-essential amino acids and
1 mM sodium pyruvate. Cells were grown at 37oC in a humidified atmosphere
containing 5% CO2.
3.2 Materials
Thiosalicylic acid (minimum 95%), thimerosal (minimum 97% HPLC),
Ponceau S, 12-O-tetradecanoylphorbol 13-acetate (TPA), sodium pyruvate, 3(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide, ethidium bromide,
ethylenediaminetetraacetic acid (EDTA), and N-acetylcysteine were obtained
from Sigma-Aldrich Chemical Corp. (St. Louis, MO). Hoescht 33342, Trolox, and
JNK inhibitor II (SP600125) was obtained from Calbiochem (San Diego, CA).
Cell culture media, fetal bovine serum and antibiotics were obtained from
Invitrogen Corp. (Carlsbad, CA).
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3.3 Characterization of Cell Line
The SK-N-SH cell line was examined to ensure that no significant changes
occurred in the characteristics of the cell line as the cells were passaged over
time. The cell line was tested at both a low and a high passage for consistent
doubling time and for changes in cellular markers. All subsequent experiments
were performed with cells with passage numbers in this established range.
3.3.1 Doubling Time
Cells were plated at a density of 5 X 104 cells per 60 mm plate, with the
time of plating noted. One experiment was performed at passage number 40
and one at passage number 68. Each subsequent day cells were trypsinized
and counted on a hemocytometer, noting the time the count took place each day.
The doubling time was determined by graphing the log of the cell number versus
the time (in hours), then applying the following equation:

Doubling time =

1
m

x log2

where m=slope of the line. The doubling time for cells at passage number 40 was
26.9 hours (Figure 3.1), and the doubling time for cells at passage number 68 was
25.7 hours (Figure 3.2).
3.3.2 MAP2 and SYP
We chose to investigate if two different cellular markers remained
unchanged during increasing cell passage numbers. Both proteins were assessed
at cell passage numbers 41 and 53 (Figure 3.3). The first marker was microtubuleassociated protein-2 (MAP2), which is a stringent marker for neurons. MAP2 is a
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Growth Curve-Passage No. 40
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Figure 3.1. Low passage growth curve. Cells were counted
each day. Number of cells counted and hour of cell count (time
since initial plating) were used to determine doubling time, which
was found to be 26.9 hours at passage number 40.
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Figure 3.2. High passage growth curve. Cells were counted
each day. Number of cells counted and hour of cell count (time
since initial plating) were used to determine doubling time, which
was found to be 25.7 hours at passage number 68.
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structural protein that stimulates tubulin assembly, stabilizes microtubules, and
affects spatial distribution of microtubules within cells. MAP2, which migrates at
about 300 kDa, remained unchanged throughout the passaging of the SK-N-SH
cells (Figure 3.3A).

The second cellular marker that we examined was the

synaptic vesicle protein synaptophysin (SYP).

SYP is an integral membrane

protein that is involved in the formation of synaptic vesicles. SYP levels remained
unchanged throughout the passaging of the cell line (Figure 3.3B).
3.4 Protein Analysis

Protein content was measured with the BioRad protein assay, using
bovine serum albumin (BSA) as the standard.

To determine the amount of

protein in whole cell lysates, nuclear extracts, or cytoplasmic fractions from SKN-SH cells, 5 μL of sample (or a dilution if necessary) was added to 795 μL H2O
in a 13x100 mm tube. For protein analysis of whole cell lysates from luciferase
samples, 20 μL of sample was added to 780 μL of H2O due to lower protein
concentrations. BioRad protein assay dye (200 μL) was then added to each tube
for a total volume of 1 mL. The samples were mixed on a vortex and allowed to
incubate at room temperature for 5 minutes. The BSA standards for the assay
were made using a 50 mg/mL BSA stock solution to make a 50 μg/mL BSA
working solution. Protein standards for the standard curve were prepared by
making serial dilutions from the working solution.

As with samples, 200 μL

BioRad protein assay dye was added to each tube, and the samples were mixed
on a vortex. Absorbance of standards and samples was read at 595 nm using
the Versamax spectrophotometer and SpotMax Software (Molecular Devices,
Sunnyvale, CA).

Software determined protein content of samples based on

optical density values on standard curve.
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p41

A

MAP2

B

SYP

p53

Figure 3.3. Characterization of SK-N-SH cell line. Microtubuleassociated protein-2 (MAP2), a stringent marker for neurons, and
synaptophysin (SYP), an integral membrane protein that is
involved in the formation of synaptic vesicles, were assessed with
Western blotting of whole cell lysates of cells at passage 41 and
53. 50 μg of protein loaded each lane.
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3.5 Treatment of Cells with Thimerosal
Cells were treated with a range of thimerosal concentrations (0-10 μM),
and thiosalicylate was used as a control to ensure that changes noted following
treatment were attributed to the mercury-containing portion of the thimerosal
molecule.

The concentration of thiosalicylate corresponded to the highest

concentration of thimerosal used in each individual experiment. A stock solution
of 1 mM thimerosal or thiosalicylate was prepared in medium and appropriate
dilutions were made to achieve the final treatment concentrations for each
experiment.
3.6 Cell Viability Assays
3.6.1 Lactate Dehydrogenase (LDH) Assay
Cells were seeded in 2 mL of media in 6-well plates.

At 80-90%

confluency, cells were treated 0-10 μM thimerosal in replicates of three. Cells
were incubated for 24 or 48 h, followed by removal of medium and centrifugation
to pellet floating cells. The supernatant was removed and placed in a separate
tube on ice. Five hundred microliters of 0.2% Triton X was added to each well,
and cells were scraped and added to the cells pelleted from the medium. Each
well was washed with 500 μL of water, which was also added to the tube with the
cells. The tubes were vortexed for 1 min, centrifuged, and placed on ice. βNADH solution was prepared by dissolving 2 mg β-NADH in 28.5 mL of 0.1 M
potassium phosphate buffer (pH 7.5). Fifty microliters of sample was added to
920 μL β-NADH solution and incubated at room temperature for 20 min. After
incubation, 30 μL of 22.7 mM sodium pyruvate solution was added and the
absorbance was read at a wavelength of 340 nm at 25°C. Readings were taken
every 15 s for 2 min (Stasar II, Gilford, Nova Biotech, El Cajon, CA) to determine
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the absorbance change per min, which was used to calculate LDH activity with
the following equation:
LDH activity (μmol/L) = dA/min/6.22/0.05 X 1000
where dA is the change in absorbance (Loo and Rillema, 1998).

The LDH

activity of the medium was compared to the total LDH activity (total of tissue and
medium).
3.6.2 MTT Assay
Cells were seeded in a 96-well flat-bottom plate at a density of 4 X 104
cells per well in 100 μL of medium. After 24 h, thimerosal-containing medium
was added to the cells with final concentrations of 0-10.0 μM in a total volume of
200 μL. Cells were treated in replicates of five wells each with medium used as a
blank. Cells were treated for either 24 or 48 h. 3-(4,5-dimethylthiazolyl-2-yl)-2,5diphenyltetrazolium bromide (MTT) was prepared by dissolving 5 mg/mL in
phosphate buffered saline (PBS; pH 7.4) and then sterile filtered. Four hours
before the end of the incubation period, 10 μL of MTT was added to each well.
At the end of the treatment period, 100 μL of 0.1 N isopropanol/HCl was added to
each well and mixed by repeated pipetting to dissolve granules. Absorbance
was measured on a plate reader (Molecular Devices Corp., Sunnyvale, CA) at a
wavelength of 570 nm (Mosmann, 1983). Results were reported as percentage
of control.
3.7 Fluorescent Microscopy
SK-N-SH cells were plated in 6-well plates at a density of 5 x 105 cells per
well. After 24 h, medium was removed and replaced with fresh media containing
either thiosalicylate (5 µM) or thimerosal (5 µM). At the end of the treatment
period (24 h), medium was removed from each well, placed in 50 mL tubes, and
stored on ice. Wells were washed twice with PBS, and each time the PBS was
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combined with the corresponding medium on ice. After the washes, 2 mL of 1
mM EDTA (in PBS) was added to each well and allowed to incubate at room
temperature until cells were floating. This suspension was then added to the
appropriate tubes on ice. Tubes were centrifuged at 200 x g for 10 min. The
supernatant was discarded, cells were washed in 1 mL PBS, and centrifuged as
previously described. After removal of the supernatant, cells were resuspended
in 100 µL PBS. Cells were then stained in suspension with Hoescht 33342 (2
µg/mL) and ethidium bromide (5 µg/mL) for 15 min. Cells were examined at 380
nm using a Microphot-SA microscope (Nikon) and Spot RT Software (Spot
Diagnostic Instruments, Inc., Sterling Heights, MI) (Katsen et al., 1998).
Apoptotic cells were identified by nuclear condensation and DNA fragmentation
(Squier and Cohen, 2000).
3.8 Cell Counts for Apoptotic and Necrotic Cells
Cell counts were performed on fluorescently stained slides as above after
24 h treatment and counted on the same microscope. For each treatment 100
cells were counted, and each experiment was performed three times. Statistical
analysis was performed as indicated below. Apoptosis was assessed by nuclear
fragmentation and condensation, and necrosis was assessed by swelling and
uptake of ethidium bromide (pink color).
3.9 Isolation of Cytoplasmic Fractions, Nuclear Extracts, and Whole Cell Lysates
Cytoplasmic fractions, nuclear extracts, and whole cell lysates were
prepared by washing cells twice in cold PBS. For whole cells lysates, cells were
resuspended in phosphate lysis buffer, vortexed, and frozen prior to analysis.
For cytoplasmic fractions and nuclear extracts, cells were initially resuspended in
lysis buffer (10 mM HEPES-KOH, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol (DTT), 5 mM NaF, 1 mM Na3VO4, Complete Mini (15%; Roche,
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Indianapolis, IN), H2O) and incubated on ice for 15 min. After incubation, 10%
NP-40 was added, the suspension was vortexed for 15 sec and centrifuged for
30 sec at 14,000 rpm. The supernatant, containing the cytoplasmic fraction, was
removed and frozen at –80˚C until analyzed. The pellet was resuspended in a
second buffer (20 mM HEPES-KOH, 1.5 mM MgCl2, 420 mM NaCl, 35% glycerol,
0.5 mM DTT, 5 mM NaF, 1 mM Na3VO4, Complete Mini (15%), H2O) and
incubated on ice for 20 min. The suspension was then centrifuged at 12,000 rpm
for 2 min. The supernatant, containing the nuclear extract, was removed and
frozen at –80˚C until analyzed.
3.10 Subcellular Fractionation
The mitochondrial fraction of SK-N-SH cells was prepared by washing the
cells twice in cold PBS, followed by resuspension in 5 ml of 0.25 M sucrose, 1
mM ethylene glycol tetra acetic acide (EGTA), and 10 mM Tris-HCl (pH 7.4) and
centrifuging at 500 x g for 2 min at 4oC. The supernatant was discarded and the
cells were resuspended in 5 ml of the same buffer. The cells were homogenized
in a glass Teflon homogenizer using 10 up-and-down strokes at 500 rpm. The
homogenate was centrifuged at 1500 x g for 10 min at 4oC. The supernatant
was removed and recentrifuged at 10,000 x g for 10 min. The pellet, which
contained mitochondria, was resuspended in 50 μL of buffer. The supernatant
was recentrifuged at 100,000 x g (4oC, 1 h) to generate the S-100 fraction.
Protein concentration of both fractions was determined by a colorimetric assay
(BioRad Laboratories, Hercules, CA).
3.11 Caspase-3 Protease Activity
Activation of caspase 3 was determined using the ApoAlert assay kit
(Clontech Laboratories, Palo Alto, CA), which fluorometrically detects caspase 3
activity using proteolytic cleavage of the fluorophore 7-amino-4-trifluoromethyl
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coumarin (AFC) from the substrate conjugate DEVD-AFC. Cells were plated (6 x
105) in 100 mm dishes and treated with 0-5 μM thimerosal for 0-24 h. Cells (2 x
106) were collected at various time points after treatment, lysed on ice,
centrifuged (12,000 rpm x 3 min) and the supernatants were collected and stored
at -70oC until further use. Cell lysates were incubated with DEVD-AFC in the
presence of dithiothreitol for 1 h at 37oC. Detection of AFC was measured using
a 400 nm excitation filter and a 530 nm emission filter. Caspase 3 activity is
expressed as percent control.
3.12 Western Analysis
Cytoplasmic

(p-JNK,

glyceraldehyde-3-phosphate

dehydrogenase

[GAPDH]), nuclear extracts (p-JNK, cJun, cFos, p-cJun(Ser63), p-cJun(Ser73), βactin) or whole cell lysates (Bim/BOD, Cleaved Caspase 3, Caspase 9, PARP,
MAP2, SYP, GAPDH) were electrophoresed on a 7% (MAP2 only) or 12.5% SDSPAGE (SDS-polyacrylamide gel electrophoresis) according to the method of
Laemmli (1970) and transferred to nitrocellulose membrane. Transfer efficiency
was assessed by staining with 0.1% Ponceau S, and then blots were washed with
distilled water to remove stain. Blots were blocked for 1 h at room temperature in
Blotto (5% milk, 10 mM Tris-HCl, 150 mM NaCl (pH 8.0), 0.05% Tween-20) or 5%
dry milk in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20 [pH 8.0]; p-JNK,
p-cJun [Ser63], p-cJun [Ser73]). Each blot was incubated overnight at 4°C with
the primary antibody at a dilution of 1:1000 in Blotto (cJun, cFos, Santa Cruz
Biotechnology, Inc., Santa Cruz, CA; Bim/BOD, Stressgen, Victoria, British
Columbia, Canada; Cleaved Caspase 3, Caspase 9, PARP, Cell Signaling
Technology, Inc., Beverly, MA; MAP2, Chemicon International, Temecula CA;
SYP, Santa Cruz Biotechnology, Inc.; GAPDH (1:10,000), Trevigen, Gaithersburg,
MD; β-actin (1:10,000), Sigma-Aldrich Chemical Corp., St. Louis, MO) or 5%
bovine serum albumin (BSA) in TBST (p-JNK, p-cJun(Ser63), p-cJun(Ser73), Cell
Signaling Technology, Inc., Beverly, MA). The next day each blot was washed
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twice with TBST and then incubated with an anti-mouse IgG (1:10,000) or antirabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology,
Santa Cruz, CA) at a 1:3000 dilution in Blotto or 5% milk solution in TBST (p-JNK,
p-cJun[Ser63], p-cJun[Ser73]) for 1.5 h at room temperature. Protein bands were
then visualized using the enhanced chemiluminescence detection system
(Amersham, Little Chalfont, UK).

All Western blots in Results section are

representative of at least three experiments.
3.13 Transient Transfection

Cells were plated at a density of 3 x 106 cells per 100 cm plate and grown
overnight.

Cells were transfected using the calcium phosphate method, and

were transfected with the pGL2 empty vector or with 1 μM of the AP-1 construct,
or co-transfected with the AP-1 construct and either A-Fos (0.125 μg or 0.25 μg)
or TAM67 (0.25 μg or 0.5 μg). The AP-1 construct, which was a generous gift
from Dr. Richard Niles, consists of four consensus sequences inserted into the
pGL2 vector (Promega, Madison, WI).

The A-Fos construct is a dominant

negative consisting of an N-terminal acidic extension added to cFos and cloned
into the CMV-500 vector (Steinmuller et al., 2001).

This construct was a

generous gift from Dr. Charles Vinson (National Institutes of Health). The TAM67
construct is a cJun dominant negative that lacks the transactivation domain and
was cloned into the pcDNA3.1(-) vector (Brown et al., 1994). This construct was
a generous gift from Dr. Michael Birrer (National Institutes of Health).

Both

dominant negative forms retain the ability to dimerize with cJun and cFos
proteins and bind DNA; however, structural alterations prevent AP-1-mediated
transcriptional events. Seven hours after transfection, cells were washed twice
with phosphate buffered saline (PBS; 137 mM sodium chloride, 3 mM potassium
chloride, 1 mM potassium phosphate, and 10 mM sodium phosphate), and fresh
media was added. On the following day, cells were trypsinized and plated in 24well plates at a density of 1.5 x 105 cells per well. Twenty-four hours later cells
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were treated in triplicate with 0-2.5 μM thimerosal or 100 nM TPA. After 24 h,
cells were washed with PBS and lysed using 200 μL of Passive Lysis Buffer
(Promega). Reporter assays were performed using the Luciferase Assay System
(Promega) and TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA).
Additional experiments were conducted using cells co-transfected with
AP-1 and 0.5 μg TAM67.

Following transfection as above, these cells were

plated in 100 mm dishes at a density of 1 x 106 cells per plate. After 24 h, cells
were treated with either 2.5 μM thiosalicylate (control) or thimerosal for 24 h, and
then whole cell lysates were collected and analyzed by Western blotting. All
transient transfection experiments were performed at least three times.
3.14 Treatment with JNK Inhibitor II (SP600125)

SP600125 is an anthrapyrazolone compound that is a JNK-specific,
reversible, ATP-competitive inhibitor (Bennett et al., 2001). Preliminary studies
were conducted to determine the lowest concentration of SP600125 needed to
block thimerosal-mediated phosphorylation of cJun (Figure 3.4). Based on visual
examination of Western blotting for cJun (Ser 73), all further experiments were
carried out using 10 μM JNK inhibitor II (SP600125) or equal volumes DMSO
(vehicle) prior to thimerosal treatment (2 h pretreatment).

3.15 Treatment with Trolox

Trolox (TX) is a vitamin E analog with antioxidant properties. Trolox was
prepared by dissolving in 100% ethanol to make a 0.5 M stock solution. Cells
were pretreated for 2 h with 1 mM Trolox or equal volumes ethanol (vehicle)
before thimerosal treatment was added.
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Figure 3.4 Determination of JNK inhibitor II (SP600125)
concentration.
SK-N-SH cells were treated with 5 μM
thiosalicylate with DMSO (Lane 1) or with 10 μM SP600125 (Lane
2) or with 5 μM thimerosal with DMSO (Lane 3) or 1 μM (Lane 4), 5
μM (Lane 5), or 10 μM (Lane 6) SP600125. Cytosolic samples
were assessed with Western blotting for phosphorylated cJun (Ser
73) to determine the lowest concentration of SP600125 that
reduced JNK activity as seen by a decrease in phosphorylation of
cJun.
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3.16 Treatment with N-Acetylcysteine

N-Acetylcysteine (NAC) is a precursor in glutathione synthesis, as well as
a thiol-containing molecule capable of binding to thimerosal. NAC was prepared
by dissolving in medium to make a 0.5 M stock solution. Cells were pretreated
for 2 h with 1 mM NAC. Prior to treatment NAC was removed. Then cells were
treated with thiosalicylate or thimerosal (no NAC pretreatment), or thimerosal
with or without NAC added back to treatment, and NAC alone.
3.17 Statistical Analysis
Statistical analysis was performed using SigmaStat software (SPSS, Inc.,
Chicago, IL). Results were assessed with t-test or analysis of variance using
Tukey’s test or Dunnett’s test with a p-value of 0.05.
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CHAPTER IV
Results
4.1 Morphological Changes Upon Thimerosal Treatment

To determine if thimerosal induced toxicity in a human neuroblastoma cell
line (SK-N-SH), cells were treated with a range of concentrations (0-5 μM), and
then visualized and photographed using a Nikon Phase Contrast microscope.
Within 2 h of exposure, membrane alterations could be visualized, followed by
cell shrinkage and detachment (Figure 4.1). Observed morphological changes
upon thimerosal administration were consistent with reports of mercurialmediated cytoskeletal toxicity (Duhr et al., 1993; Kinoshita et al., 1999). In this
model, we showed cytoskeletal changes at concentrations of thimerosal
significantly below those previously reported by Kim et al. (2002) in treatment of
HeLa S cells (20 μM).

Additionally, morphological changes such as those

described above suggest that thimerosal may induce apoptotic cell death (Lincz,
1998).
4.2 Lactate Dehydrogenase (LDH) Assay

To further evaluate toxicity, activity of LDH, a cytosolic enzyme released
into surrounding media during cell death, was measured. LDH is a ubiquitous
enzyme involved in the conversion of lactate to pyruvate, as well as the reverse
reaction, during glucose metabolism.
LDH

Pyruvate + NADH + H+
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Lactate + NAD+

A

B

C

D

Figure 4.1. Thimerosal induces cytoskeletal and membrane
changes. Morphological analysis of SK-N-SH cells following
treatment with either A) 5 μM thiosalicylate for 6 h; B) 5 μM
thimerosal for 2 h; C) 5 μM thimerosal for 4 h and D) 5 μM
thimerosal for 6 h. No changes in morphology were noted in the
thiosalicylate treated cells, whereas thimerosal caused alterations
of membranes (arrow). In addition, cell shrinkage and detachment
occurred within 6 h of treatment. Cells were visualized and
photographed using a Nikon Phase Contrast Microscope.
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As the membrane loses integrity during necrosis and late apoptosis, LDH is
released. This assay approximates cell death rates by measuring enzymatic
activity of LDH as it converts pyruvate and NADH to lactate and NAD+ (Loo and
Rillema, 1998). The LDH assay indicated a concentration- and time-dependent
thimerosal-induced toxicity. At 24 h, LDH activity was significantly higher (p <
0.001) than control at 2.5, 5.0, and 10.0 μM thimerosal treatments, indicating a
loss of membrane integrity (Figure 4.2A). Extending the exposure time to 48 h
also caused a significant increase in LDH activity with 1.0 μM thimerosal (Figure
4.2B).

4.3 3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) Assay

The MTT assay is a colorimetric assay for cytotoxicity. MTT is cleaved to
a blue formazan product by dehydrogenase enzymes of intact mitochondria,
allowing for determination of cell viability (Mosmann, 1983). As with the LDH
assay, thimerosal treatment of SK-N-SH cells induced toxicity in a concentrationand time-dependent manner. At 24 h, cell viability was significantly decreased
with 5.0 and 10.0 μM thimerosal in comparison to the control (Figure 4.3A). At
48 h, cell viability was also significantly decreased at 1.0 μM and 2.5 μM
concentrations (Figure 4.3B).

Results from the MTT experiments paralleled

those obtained with the LDH assay in that extended exposure times with lower
thimerosal concentrations also led to cytotoxicity.

4.4 Fluorescent Analysis of Cell Death
LDH leakage can occur as a result of late stage apoptosis or necrosis.
Therefore, we used fluorescence microscopy with DNA staining to determine if one
or both types of cell death were occurring as a result of thimerosal exposure.
48

LDH Activity (% total)

A

100
90
80

+

70
60
50
40
30

+

+

20
10
0
Control

0.1 uM

1.0 uM

2.5 uM

5.0 uM

10.0 uM

Thim erosal Concentration

B

24 h

LDH Activity (% total)

100
90

+

80
70

+

60
50
40

+

30
20

+

10
0
Control 0.1 uM

1.0 uM

2.5 uM

5.0 uM 10.0 uM

Thim erosal Concentration

48 h
(+) p<0.001

Figure 4.2. Thimerosal treatment induces LDH release from
SK-N-SH cells. Enzymatic activity of LDH in medium was
measured at 24 and 48 h in cells treated with a range of
thimerosal concentrations (0-10.0 μM) or 10.0 μM thiosalicylate.
Results are presented as percentage of LDH activity in medium in
comparison to total LDH activity (total of tissue and medium).
+P<0.001. Results shown are representative of at least three
experiments at each time point.
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Figure 4.3. Thimerosal-treated cells show decreased cell
viability. Cell survival was determined by the MTT assay at 24
and 48 h in cells treated with a range of thimerosal concentrations
(0-10.0 μM) compared to control (10.0 μM thiosalicylate).
*P<0.05; +P<0.001, n=6 (for each time point).
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Fluorescent analysis of cell death as described by Katsen et al. (1998) and
Thevenod et al. (2000) was conducted using both Hoescht 33342, which is
membrane permeable, and ethidium bromide, which is not membrane
permeable. Under ultraviolet epi-illumination necrotic cells fluoresce pink due to
ethidium bromide uptake, whereas normal and apoptotic cells emit blue
fluorescence due to Hoescht 33342 incorporation. Apoptotic cells, distinguished
from normal cells based on condensation and fragmentation of nuclei, are
depicted in Figure 4.4 (arrows). In addition, several cells stained with ethidium
bromide, suggesting that a 24 h exposure to 5 μM thimerosal results in both
apoptotic and necrotic morphologies. However, some of these cells were small
and round, rather than large and swollen, which may indicate that instead of
being necrotic cells, some of these cells showing pink fluorescence were actually
apoptotic bodies.

4.5 Cell Counts for Apoptotic and Necrotic Cells

Cell counts for apoptotic and necrotic cells indicated that the number of
apoptotic cells was significantly increased following 2.5 and 5 μM thimerosal
treatment for 24 h in comparison to control.

On the contrary, the number of

necrotic cells at both concentrations was not significantly different from control
(Figure 4.5).
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Control

5 μM Thimerosal

24 h

Figure 4.4.
DNA staining shows thimerosal-induced
apoptosis. Cells were analyzed by fluorescence microscopy using
Hoescht 33342 and an ethidium bromide counterstain after a 24 h
exposure of either 5 μM thiosalicylate or thimerosal. Normal and
apoptotic nuclei stain blue, and nuclei stain pink in cells upon loss
of membrane integrity (necrosis or late apoptosis). Arrows indicate
DNA fragmentation and condensation in cells receiving 5 μM
thimerosal.
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Figure 4.5. Thimerosal induces apoptosis. Apoptotic cells were
increased significantly following both 2.5 and 5 μM thimerosal (TM)
treatment at 24 h. Fluorescently stained cells were assessed for
either apoptotic (condensed and fragmented nuclei) or necrotic
(swelling and uptake of ethidium bromide) characteristics. One
hundred cells were counted per treatment. *P<0.001. N=3.
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4.6 Thimerosal Causes Cytochrome c Translocation from the Mitochondria to the
Cytosol
Both inorganic and organic mercurials have been shown to rapidly
accumulate in mitochondria, resulting in dysfunction. Since the SK-N-SH cells
treated with thimerosal appeared apoptotic, we chose to investigate if the cell
death cascade was associated with mitochondrial release of proapoptotic
proteins. As shown in Figure 4.6, a rapid increase in the cytosolic content of
cytochrome c was observed after thimerosal administration.

4.7 Thimerosal Induces Caspase 9 Cleavage

In the mitochondrial-initiated pathway of apoptotic cell death, caspase
activation is achieved after the release of cytochrome c from mitochondria. Upon
release of the proapoptotic proteins from the mitochondria, a multimeric protein
complex consisting of Apaf-1 and cytochrome c forms, followed by recruitment
and activation of procaspase 9. Procaspase enzymes can be activated after they
are cleaved; therefore, we examined the cleavage pattern of caspase 9 in cells
treated with thimerosal.

Within 8 h of thimerosal treatment (1.0-5.0 μM)

increased generation of a 34 kDa band (Figure 4.7) was observed in addition to
the parent form of caspase 9 (46 kDa).
4.8 Thimerosal Induces Caspase 3 (CPP-32) Cleavage

Caspase 3 is a downstream target for caspase 9 activity; therefore, we
examined by Western analysis the cleavage patterns of caspase 3 following
thimerosal treatment. After 24 h of treatment, both the 17 and 19 kDa caspase 3
cleavage products were observed (Figure 4.8).
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Figure 4.6.
Cytochrome c release following thimerosal
treatment. Cells were treated with 0-5 μM thimerosal for 6 h.
Twenty micrograms of mitochondrial protein or 40 μg of the
cytoplasmic fraction was analyzed for cytochrome c by Western
analysis. By 6h, cytochrome c levels in the cytoplasm were
increased.
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Figure 4.7.
Caspase 9 cleavage following thimerosal
treatment. Caspase 9 cleavage was determined by Western
analysis in cells receiving thimerosal (0-5 μM) or thiosalicylate (5
μM) for 1 h, 4 h, and 8 h. Caspase 9 cleavage was increased at 8
h.
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Figure 4.8. Thimerosal induces cleavage of caspase 3. Cells
were treated with 1 or 5 μM thimerosal or 5 μM thiosalicylate (Ct)
for 24 h. Cytosolic fractions were analyzed with Western blotting to
detect caspase 3 cleavage products and procaspase (32 kDa).
Cleavage products were detected at 24 h following 5 μM thimerosal
treatment.
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4.9 Caspase 3 Activity Increases in a Concentration- and Time-dependent Manner

The activity of caspase 3 during thimerosal-induced apoptosis in SK-N-SH
cells was measured using the ApoAlert assay kit by Clontech. Cells were treated
with 0-5 μM thimerosal and samples were collected at various time points from 024 h.

Figure 4.9 shows a concentration- and time-dependent increase in

caspase 3 activity. At 6 h caspase 3 activity had increased 12 fold in the 5 μM
treated cells with no increase noted at 1 μM thimerosal. At 24 h both 1 and 5 μM
treated cells had significantly higher caspase 3 activity than control, 16 and 22
fold, respectively. The increase in caspase 3 activity paralleled the cleavage
pattern observed in Figure 4.8. The use of the fluorescence-based ApoAlert
assay provided greater sensitivity than Western analysis, allowing detection of
changes in caspase 3 activation at earlier time points. Caspase cleavage was
easily detected by Western analysis at the 24 h time point, consistent with the
fluorescent-based assay.
Caspase 8 can activate caspase 3 independent of mitochondrial events
leading to apoptosis; however, in our studies we found no activation of caspase 8
(data not shown), suggesting initiation of cell death signals by thimerosal at the
level of the mitochondria.

4.10 Thimerosal Induces Poly(ADP-ribose) Polymerase (PARP) Cleavage

PARP, a DNA nick sensor, is a substrate for cleavage by activated
caspase 3. The data shown in Figure 4.10 indicates that thimerosal induces
PARP cleavage. At 24 h, 5 μM thimerosal treatment caused degradation of the
116 kDa parental PARP protein accompanied by generation of
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Figure 4.9. Caspase 3 activity. SK-N-SH cells were treated with
0-5 μM thimerosal for 1 h, 6 h, or 24 h. The ApoAlert fluorescence
detection assay was used to determine caspase 3 activity.
Caspase 3 activity was detected at 6 h following 5 μM thimerosal
treatment, and at 24 h following 1 and 5 μM thimerosal treatment.
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5.0 μM Thimerosal
Parental PARP 116 kDa
Cleaved PARP 85 kDa

Figure 4.10. Thimerosal induces cleavage of PARP. PARP, a
116 kDa downstream target of activated caspase 3, was analyzed
by Western analysis in cells receiving 0-5 μM thimerosal. Cells
treated with 5 μM thiosalicylate showed minimal cleavage; whereas
SK-N-SH cells receiving thimerosal contained an abundant 85 kDa
cleavage product after 24 h.
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an 85 kDa immunoreactive cleavage product (Figure 4.10). No cleavage was
observed following 12 h of treatment with 1 μM thimerosal (data not shown).
4.11 Thimerosal Induces Phosphorylation of JNK

The JNK pathway is activated by cellular stresses, resulting in the
phosphorylation of cJun N-terminal kinase, which then phosphorylates proteins,
including transcription factors. To determine if thimerosal activates this signaling
pathway, SK-N-SH cells were treated with a range of thimerosal concentrations (010 μM) for 2 and 4 h.

Western blotting showed an increase of JNK

phosphorylation at 5 and 10 μM at both time points in comparison with
thiosalicylate (Figure 4.11). The activated JNK was present in both the cytoplasm
(Figure 4.11A) and the nucleus (Figure 4.11B). Multiple bands are visible, and
may be because the three JNK genes encode 10 JNK isoforms, and these splice
variants migrate at either 46 kDa or 54 kDa (Davis, 2000). Lower concentrations of
thimerosal required longer incubation times to activate JNK. For instance, cells
treated with 2.5 μM thimerosal began to show increases in p-JNK at 6 h (Figure
4.11C). This MAPK induction was specific for JNK; p38 and extracellular signalregulated kinase (ERK) were not activated in response to thimerosal (data not
shown). Activated JNK in the nucleus is significant because this is a potential site
of interaction with transcription factors, including AP-1.

Activated JNK in the

cytoplasm is also important because this is a second site of interaction with cellular
components, including proteins mediating apoptosis.
4.12 Thimerosal Treatment Causes Increases in cJun and cFos

Activator Protein-1 most often consists of dimerized proteins from the cJun
and cFos families.

Transcription factors from the cJun family can form either

homodimers or heterodimers with members of the cFos family. To determine if
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Figure 4.11. Thimerosal induces phosphorylation of JNK.
Cells were treated with a range of thimerosal concentrations (0-10
μM) for 2 and 4 h. Western analysis was performed to assess
increases in phosphorylation of JNK in both cytoplasmic samples
(A) and nuclear extracts (B) in comparison to control (Ct; 150 μg
protein per lane-cytoplasmic samples; 40 μg protein per lanenuclear extracts). Cells were also treated with 2.5 μM thimerosal
for 6 h and Western analysis was performed on both nuclear
extracts and cytoplasmic samples (C) in comparison to control (75
μg protein per lane-cytoplasmic samples; 50 μg protein per lanenuclear extracts). GAPDH (A) or β-actin (B and C) was used as a
loading control.
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Figure 4.12. Thimerosal causes increases in cJun and cFos
levels. Western blotting of nuclear extracts showed that cells
treated with 5 μM thimerosal for 4 h and 10 μM thimerosal for 2 or
4 h had increases in total cJun (A) and cFos (B) levels, with cJun
also showing an increase with 2.5 μM at 4 h. 40 μg of protein
loaded per lane. β-actin was used as a loading control.
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protein levels of either cJun or cFos were increased in response to thimerosal
exposure, we treated SK-N-SH cells with a range of thimerosal concentrations (010 μM) for 2 and 4 h and collected nuclear extracts. Western blotting of nuclear
extracts showed that cells treated with 10 μM for 2 h had increases in total cJun
and cFos levels (Figure 4.12). Extending treatment time to 4 h showed increases
in cJun levels with 2.5-10 μM thimerosal treatment in comparison to control (Figure
4.12A), while cFos levels were increased with 5-10 μM thimerosal treatment
(Figure 4.12B).

However, increased protein levels do not necessarily indicate

activation of transcription factors, which must first be phosphorylated to be
activated.
4.13 Thimerosal Induces Phosphorylation of cJun (Ser 63 and Ser 73)

Phosphorylation of cJun, which indicates activation, was determined
following thimerosal treatment. Nuclear extracts of SK-N-SH cells treated with a
range of thimerosal concentrations (0-10 μM) for 2 and 4 h showed an increase in
cJun phosphorylation at 5 and 10 μM at both time points in comparison with
control (Figure 4.13).

cJun phosphorylation was increased at both serine 63

(Figure 4.13A) and serine 73 (Figure 4.13B); phosphorylation of both sites has
been shown to maximally enhance cJun activity (Smeal et al., 1991).
4.14 Thimerosal Activates AP-1 Transcriptional Activity Through cJun But Not
cFos

To further investigate the activation of the JNK/AP-1 pathway, we next
looked at AP-1 transcriptional activity. We transfected SK-N-SH cells with the
pGL2 empty vector or the AP-1 construct using a luciferase reporter assay system.
Cells treated with 2.5 μM thimerosal showed a significant increase in luciferase
activity, indicating an increase in AP-1 transcriptional activation. Transfected cells
64

2h
Ct 1

2.5

4h
5 10

Ct 1

2.5

5

A

10

μM thimerosal
Ser 63
β-actin

2h

B

Ct 0.1 1 2.5

4h
5 10 Ct 0.1 1 2.5 5 10

μM thimerosal
Ser 73
β-actin

Figure 4.13. Thimerosal causes activation of cJun. Cells
treated with 5 and 10 μM thimerosal showed increases in
phosphorylation of cJun in nuclear extracts at 2 and 4 h at both
serine 63 (A) and serine 73 (B) in comparison to control, as well as
an increase at 2.5 μM thimerosal at Ser 73. 25 μg of protein
loaded per lane. β-actin was used as a loading control.
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were also treated with 100 nM TPA, a known activator of AP-1 transcriptional
activity that served as a positive control (Figure 4.14, 4,15). We next used the AFos dominant negative to determine the role of cFos in this pathway.

Cells

transfected with the AP-1 luciferase reporter construct alone or cotransfected with
(0.125 μg or 0.25 μg) A-Fos showed comparable increases in luciferase activity,
suggesting that cFos is not part of this AP-1 complex activated by thimerosal
(Figure 4.14).

The TPA-induced increase in luciferase activity was inhibited,

indicating that the A-Fos construct was able to block AP-1 transcriptional activity
(Figure 4.14). The TAM67 dominant negative was used to determine the role of
cJun in this pathway. Cells cotransfected with the cJun dominant negative and
AP-1 luciferase reporter construct did not show increases in luciferase activity
following thimerosal treatment, indicating blockage of AP-1 transcriptional activity
(Figure 4.15). This suggests that cJun is playing an active role in thimerosalinduced AP-1 transcriptional activation, possibly by forming a homodimer.
4.15 Thimerosal Treatment Increases Levels of Proapoptotic Bim

Bim is a proapoptotic member of a subgroup of the Bcl2 family of proteins
that contain only the Bcl2-homology 3 (BH3) domain. These proteins interact
with and inactivate anti-apoptotic Bcl2 family members in response to cellular
stress, such as DNA damage (Bouillet et al., 2001). Bim may also be directly
activated by JNK, leading to mitochondrial-mediated apoptosis. Additionally, Bim
is an AP-1 target gene; therefore, we wanted to determine if Bim was associated
with thimerosal-induced toxicity in this cell line.

In cells treated with 2.5 μM

thimerosal for 24 h, Western blotting showed that Bim levels were increased in
comparison with control (Figure 4.16A, Lanes 1 and 3).
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Figure
4.14.
Thimerosal
treatment
increases
AP-1
transcriptional activation, but does not involve cFos. Cells
were transfected with the empty vector (black bars) or AP-1 vector
(open bars) or the AP-1 vector with 0.125 μg A-Fos (diagonally
hatched bars) or 0.25 μg A-Fos (horizontally hatched bars),
followed by 24 h treatment with 0-2.5 μM thimerosal (TM), or the
positive control, TPA (100 nM). Luciferase activity was measured,
normalized to protein, and reported as fold change in comparison
to control. * P< 0.05 vs. Empty Vectors,† P<0.05 vs. AP-1 Reporter
Construct, n=3.
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Figure
4.15.
Thimerosal
treatment
increases
AP-1
transcriptional activation through cJun. Cells were transfected
with the empty vector (black bars) or AP-1 vector (open bars) or the
AP-1 vector with 0.25 μg TAM67 (diagonally hatched bars) or 0.5
μg TAM67 (horizontally hatched bars), followed by 24 h treatment
with 0-2.5 μM thimerosal (TM), or the positive control, TPA (100
nM). Luciferase activity was measured, normalized to protein, and
reported as fold change in comparison to control. * P< 0.05 vs.
Empty Vectors,† P<0.05 vs. AP-1 Reporter Construct, n=4.
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4.16 Pretreatment with JNK inhibitor II (SP600125) Blocks Increases in Bim and
Other Apoptotic Proteins

To confirm that JNK is an essential component of this thimerosal-induced
mitochondrial-mediated apoptotic pathway, we chose to use the cell-permeable
JNK inhibitor II (SP600125). By blocking the activation of JNK and its subsequent
ability to activate transcription factors and other cellular proteins, we can determine
if it is playing a role in thimerosal-mediated apoptosis.

SK-N-SH cells were

pretreated for 2 h with 10 μM SP600125 followed by 2.5 μM thimerosal for 24 h, as
above, and then examined with Western blotting.

Cells pretreated with the

inhibitor followed by thimerosal administration showed less of an increase in levels
of Bim (Figure 4.16A), cleaved caspase 9 (Figure 4.16B), cleaved caspase 3
(Figure 4.16C), and cleaved PARP (Figure 4.16D), than did cells treated with
thimerosal alone, indicating that blockage of the JNK pathway has a protective
effect on the cells.

To confirm this, cells were examined microscopically for

morphological changes.

The SP600125-pretreated cells showed morphology

similar to control cells, while those treated with thimerosal alone showed
morphological changes evident of toxicity as previously described (Humphrey et
al., 2005; Figure 4.17).
4.17 Blockage of cJun Transcriptional Activity Does Not Prevent Apoptosis

After we established that JNK was essential to thimerosal-induced neuronal
apoptosis, we investigated whether this response was also dependent on cJun
activation. Cells were again transfected with TAM67, and whole cell lysates were
analyzed

by

Western

blotting

for

changes

in

apoptotic

parameters.

Untransfected cells and those transfected with empty vectors or AP-1 luciferase
reporter construct showed increases in caspase 3 cleavage when treated with
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Figure 4.16. JNK inhibitor II (SP600125) decreases markers of
apoptosis. In Figures A-D Lane 1 represents SK-N-SH cells
pretreated for 2 h with vehicle followed by 24 h treatment with 2.5
μM thiosalicylate (Ct w/o inh). Lane 2 represents cells pretreated
for 2 h with 10 μM SP600125 followed by 24 h treatment with 2.5
μM thiosalicylate (Ct w/ inh). Lane 3 represents cells pretreated for
2 h with vehicle followed by 24 h treatment with 2.5 μM thimerosal
(2.5 μM w/o inh). Lane 4 represents cells pretreated with 10 μM
SP600125 followed by 24 h treatment with 2.5 μM thimerosal (2.5
μM w/ inh). Western blotting was performed on whole cell lysates
to assess changes in levels of Bim (A), cleaved caspase 9 (B),
cleaved caspase 3 (C), and cleaved PARP (D). 50 μg of whole cell
lysates loaded per lane. GAPDH was used as a loading control.
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A
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C

D

Figure 4.17. SP600125 has a protective effect following
thimerosal treatment. Cells were pretreated for 2 h without (A, C)
or with (B, D) SP600125 and treated with 2.5 μM thiosalicylate (A,
B) or 2.5 μM thimerosal (C, D), and then observed microscopically
for morphological changes. Arrows indicate cells displaying toxicity.
Cells were observed with a Nikon Diaphot (Frank E. Fryer Co.,
Cincinnati, OH) and photographed using a Nikon N2000 camera.
Cells pretreated with SP600125 before thimerosal treatment show
decreased toxicity in comparison to cells treated with thimerosal
alone.

71

thimerosal in comparison to thiosalicylate (Figure 4.18A). Cells transfected with
TAM67 still underwent apoptosis when treated with 2.5 μM thimerosal, as seen
by similar increases in cleaved caspase 9 (Figure 4.18B), cleaved PARP (Figure
4.18C), and Bim (Figure 4.18D). These results indicate that cJun activation is
not an essential component of apoptosis in response to thimerosal exposure.

4.18 JNK Inhibitor II (SP600125) Decreases Heme Oxygenase-1 (HO-1) Levels

Previous studies in our lab have shown that SK-N-SH cells mount a stress
response following thimerosal treatment. One indicator of this stress response is
an increase in HO-1 (Marcelo et al., 2006). To determine if this stress response is
influenced by the thimerosal-induced activation of the JNK pathway, we used the
SP600125 JNK inhibitor, as above. SK-N-SH cells were pretreated for 2 h with 10
μM SP600125 followed by 2.5 μM thimerosal for 24 h, as above, and then
examined with Western blotting. Cells pretreated with the inhibitor followed by
thimerosal administration showed less of an increase in levels of HO-1 than did
cells treated with thimerosal alone, indicating that blockage of the JNK pathway
decreases the stress response (Figure 4.19). This decrease in HO-1 may be due
to the blockage of the apoptotic pathway by SP600125, thus decreasing the need
for a stress response, or directly through the blockage of JNK activation, which
could in turn block activation of transcription factors responsible for HO-1 gene
transcription.
4.19 Blockage of cJun Transcriptional Activity Does Not Affect HO-1 Levels

Because the AP-1 pathway was not a component of thimerosal-induced
apoptosis, we next wanted to determine if the stress response was mediated
through AP-1 transcriptional activation.

Cells were again transfected with

TAM67, and whole cell lysates were analyzed by Western blotting for changes in
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Figure 4.18. TAM67 is not protective following thimerosal
treatment. Untransfected cells (Untransfected; except for Bim blot)
and those transfected with empty vectors (Empty Vectors) or AP-1
construct (AP-1) or AP-1 construct and 0.5 μg TAM67 (TAM67)
were treated with 2.5 μM thiosalicylate (TS) or 2.5 μM thimerosal
(TM). Whole cell lysates were analyzed by Western blotting for
caspase 3 cleavage (A), caspase 9 cleavage (B), PARP (C), or Bim
(D). GAPDH was used as a loading control. 50 μg protein loaded
per lane in A and B. 15 μg protein loaded per lane in C. 20 μg
protein loaded per lane in D.
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Figure 4.19. Blocking JNK activation decreases HO-1 levels.
Lane 1 represents SK-N-SH cells pretreated for 2 h with vehicle
followed by 24 h treatment with 2.5 μM thiosalicylate (Ct w/o inh).
Lane 2 represents cells pretreated for 2 h with 10 μM SP600125
followed by 24 h treatment with 2.5 μM thiosalicylate (Ct w/ inh).
Lane 3 represents cells pretreated for 2 h with vehicle followed by
24 h treatment with 2.5 μM thimerosal (2.5 μM w/o inh). Lane 4
represents cells pretreated with 10 μM SP600125 followed by 24 h
treatment with 2.5 μM thimerosal (2.5 μM w/ inh). Western blotting
was performed on whole cell lysates to assess changes in levels of
HO-1. 50 μg of whole cell lysates loaded per lane. GAPDH was
used as a loading control.
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apoptotic parameters.

Untransfected cells and those transfected with empty

vectors or AP-1 construct showed increases in HO-1 when treated with
thimerosal in comparison to thiosalicylate. Cells transfected with TAM67 and
treated with thimerosal showed similar changes in HO-1 levels when compared
to the other transfected sets (Figure 4.20), indicating that the thimerosal-induced
increases in HO-1 are not mediated through AP-1.

4.20 Oxidative Stress Component is Upstream of JNK Activation

Previous studies in our lab indicated that following 5 μM thimerosal
exposure, oxidative stress increases as early as 1 hr after treatment (Marcelo et
al., 2006).

This time point is earlier than the time point at which JNK

phosphorylation increases (Figure 4.11). We next wanted to determine if the
oxidative stress component of thimerosal-induced neurotoxicity was upstream of
the JNK activation or was part of a separate pathway. Using the antioxidants
Trolox (TX) and N-acetylcysteine (NAC) to decrease oxidative stress, we
analyzed cytoplasmic fractions of thimerosal-treated cells with Western blotting to
look at changes in phosphorylation of JNK. Trolox is a vitamin E analog that
works at the levels of the membrane to protect the cell from damage due to
oxidative stress. NAC is a precursor to glutathione, which is the most abundant
endogenous antioxidant, and may also bind directly to sulfur-containing
compounds, such as thimerosal, to reduce oxidative stress. Following a 2 h
pretreatment with TX and either 5 or 10 μM thimerosal treatment for 4 hr (Figure
4.21A) or a 2 h pretreatment with NAC or TX and then 5 μM thimerosal treatment
for 6 hr, phosphorylation of JNK was increased in comparison to thimerosal
treatment alone (Figure 4.21B,C). This increase was transient, and following
exposure to 5 μM thimerosal for 24 h, JNK phosphorylation was decreased in
cells pretreated with NAC or TX (Figure 4.21D,E). At the lower concentration of
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Figure 4.20. TAM67 does not block HO-1 increase. Cells
transfected with empty vectors (Empty Vectors) or AP-1 construct
(AP-1) or AP-1 construct and 0.25 μg (TAM67-Low) or 0.5 μg
TAM67 (TAM67-High) were treated with 2.5 μM thiosalicylate (TS)
or 2.5 μM thimerosal (TM). Whole cell lysates were analyzed by
Western blotting for HO-1. GAPDH was used as a loading control.
50 μg protein loaded per lane.
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2.5 μM thimerosal, pretreatment with TX also caused an increase in JNK
phosphorylation by 6 hr and a decrease by 24 hr (Figure 4.22A,C).

NAC

pretreatment caused a small increase in p-JNK when NAC was included with the
treatment and no change in phosphorylation when NAC was removed, with a
slight decrease by 24 hr (Figure 4.22B,D).

The overall decrease in JNK

phosphorylation in cells pretreated with antioxidants prior to thimerosal treatment
indicates that the oxidative stress component is upstream of JNK activation. The
transient increase in JNK phosphorylation seen at 6 hr may be due to a
temporary stabilization of JNK in the phosphorylated state, perhaps due to an
effect on the phosphatases that inactivate JNK. Additionally, in some of the
Western blots, the untreated cells and cells treated with only thiosalicylate, TX, or
NAC alone appear to have a higher level of p-JNK than in cells treated with
thimerosal alone, especially with the lower concentration. On the surface this
may seem that thimerosal actually causes a decrease in p-JNK. However, this
high level of basal phosphorylation is most likely due to the serum present in the
medium used in this treatment.

The medium has to be changed when the

pretreatments are initially added and then again when the thimerosal treatments
are added. In treatments where the medium is not changed and thimerosal is
added, p-JNK is increased over control at the same time point (Figure 4.11).
Therefore, this most likely represents a differential phosphorylation in response
to two different stimuli.

4.21 Antioxidants Affect Bim Levels

We further investigated the effect of antioxidants Trolox and Nacetylcysteine on Bim levels after a 2 hr pretreatment and 24 hr thimerosal
treatment. Cells pretreated with NAC or TX followed by 2.5 or 5 μM thimerosal
and whole cell lysates were analyzed for Bim by Western blotting. NAC and TX
pretreatment decreased levels of Bim following 5 μM thimerosal treatment, and
78

NAC decreased Bim following 2.5 μM thimerosal treatment as well (Figure
4.23A,B). However, Bim levels increased with a TX pretreatment and 2.5 μM
thimerosal treatment (Figure 4.23B). This unexpected increase may be transient,
as was the increase in JNK phosphorylation. Lower concentrations of thimerosal
take longer to have effects similar to higher concentrations, as was demonstrated
with the MTT and LDH results (Figures 4.2, 4.3). Therefore, further studies could
determine if Bim levels decrease at later time points.
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Figure 4.21. Antioxidant pretreatment affects p-JNK levels
following 5 μM and 10 μM thimerosal treatment. (A) Cells were
pretreated with vehicle or 1 mM Trolox (TX) for 2 h and then treated
with either 10 μM thiosalicylate (Ct) or 5 or 10 μM thimerosal
without (5,10) or with TX (5/TX, 10/TX) for 4 h. (B) Cells were
pretreated as in A and treated with 5 μM thimerosal without (5) or
with TX (5/TX). (C) Cells were pretreated with 1 mM NAC
(dissolved in medium) for 2 h and then NAC was removed. Cells
were then treated with 5 μM thiosalicylate (Ct), NAC alone (+N),
NAC pretreatment only (-N), 5 μM thimerosal (5), 5 μM thimerosal
with NAC (5+N), or 5 μM thimerosal with NAC pretreatment only (5N) for 6 hr. (D) Same treatment as B for 24 h, and a set with no
treatment (None). (E) Same treatment as C for 24 h, and a set with
no treatment (None). 50 μg protein loaded each lane, except C,
which has 30 μg protein loaded per lane. GAPDH was used as a
loading control.
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Figure 4.22. Antioxidant pretreatment affects p-JNK levels
following 2.5 μM thimerosal treatment. (A) Cells were pretreated
pretreated with vehicle or 1 mM Trolox (TX) for 2 h and treated with
2.5 μM thimerosal without (2.5) or with TX (2.5/TX). (B) Cells were
pretreated with 1 mM NAC (dissolved in medium) for 2 h and then
NAC was removed.
Cells were then treated with 2.5 μM
thiosalicylate (Ct), NAC alone (+N), NAC pretreatment only (-N),
2.5 μM thimerosal (2.5), 2.5 μM thimerosal with NAC (2.5+N), or
2.5 μM thimerosal with NAC pretreatment only (2.5-N) for 6 hr. (C)
Same treatment as A for 24 h, and a set with no treatment (None).
(D) Same treatment as B for 24 h, and a set with no treatment
(None). 50 μg protein loaded per lane. GAPDH was used as a
loading control.
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Figure 4.23. Antioxidant pretreatment affects Bim levels
following thimerosal treatment. (A) Cells were pretreated with
vehicle (ethanol) or 1 mM Trolox (TX) for 2 h and then treated with
either 5 μM thiosalicylate (Ct) or 2.5 or 5 μM thimerosal without
(2.5,5) or with TX (2.5/TX, 5/TX) for 24 h. (B) Cells were pretreated
with 1 mM NAC (dissolved in medium) for 2 h and then NAC was
removed. Cells were then treated with 5 μM thiosalicylate (Ct),
NAC alone (+N), NAC pretreatment only (-N), 2.5 or 5 μM
thimerosal (2.5, 5), 2.5 or 5 μM thimerosal with NAC (2.5+N, 5+N),
or 5 μM thimerosal with NAC pretreatment only (5-N) for 24 hr. 25
(A) or 50 μg (B) protein loaded per lane.
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CHAPTER V
Discussion

5.1 Introduction

In the present study, the SK-N-SH cell line is used as a model for
neurotoxicity to represent the immature nervous system. A neuronal model with
the ability to differentiate is more suitable to this study than one of terminal
differentiation because one of the primary concerns with mercury exposure is the
possible effects on the developing nervous systems of fetuses, neonates, and
infants. This is particularly true with regard to the study of thimerosal, since
thimerosal-containing products are administered to neonates, infants, and
pregnant women around the world.

In addition, neuroblastoma models have

been reported to be sensitive to mercurial toxicity (Sager and Syversen, 1984;
Stoiber et al., 2004; Toimela and Tahti, 2004).
Since limited studies have been conducted to test actual mercury levels in
infants immediately following administration of thimerosal-containing vaccines, in
our initial studies, we used a range of concentrations for short and long time
periods to conduct these mechanistic studies in our model.

Subsequent

experiments used lower concentrations (1 and 2.5 μM) of thimerosal for longer
time periods in order to more easily establish events occurring following
treatment. According to Magos (2001), symptoms of toxicity occur in patients
having blood mercury levels that reach 1 μg/mL or more, which correlates to a
concentration of 5 μM thimerosal. Since limited studies have been conducted to
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test actual mercury levels in infants immediately following administration of
thimerosal-containing vaccines, we used a range of concentrations to conduct
these mechanistic studies in our model.
At the cellular level, mercurials readily react with sulfhydryl groups, making
enzymes and structural proteins likely targets. Disruption of these components
can lead to cell death.

Monnet-Tschudi (1998) demonstrated that mercuric

chloride causes apoptotic cell death in cultured astrocytes.

Kunimoto (1994)

showed that primary cultures of rat cerebellar neurons undergo apoptosis when
exposed to low concentrations of methylmercury, but undergo necrotic cell death
when exposed to higher concentrations.

Additionally, several studies have

shown that once organic mercurials enter the body, they can be converted to
inorganic mercury, which has a much longer half-life than the parent compound
(Friberg and Mottet, 1989; Norseth and Clarkson, 1970; Suda et al., 1991).
Several studies have indicated that both inorganic and organic mercurials induce
apoptosis in vitro as well as in vivo (Guo et al., 1998; Shenker et al., 1999, 2000).
At the organ level, one of the primary targets for mercurials is the brain.
Studies using Wistar rats exposed to methylmercury demonstrated that
cerebellar granule cells underwent apoptotic cell death (Nagashima et al., 1996).
With thimerosal treatment, Baskin et al., (2003) demonstrated changes in
membrane permeability, DNA damage, and caspase 3 activation in both cultured
human cerebral cortical neurons and fibroblasts. As much as 30 years ago,
researchers showed that mercury accumulated in rabbit brain tissue following the
application of thimerosal-containing ophthalmic medications (Gassett et al.,
1975) and that inorganic mercury accumulated in monkey brain tissue following
daily administration of thimerosal (Blair et al., 1975). More recently, studies have
shown that mercury accumulated in the brain tissue of neonatal mice given
intramuscular injections of thimerosal, and the levels did not decrease by 7 days
(Harry et al., 2004). Further, Hornig et al., (2004) used an autoimmune diseasesensitive mouse model (SJL/J) to show that some populations may have a
genetic predisposition for sensitivity to thimerosal-induced neurotoxicity. Similar
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studies have found that specific MHC haplotypes may be associated with
sensitivity to thimerosal toxicity (Havarinasab, 2004, 2005). However, specific
signaling

pathways

in

thimerosal-induced

neurotoxicity

have

not

been

established in animal models and are only beginning to be identified in tissue
culture models.
5.2 Toxicity Studies

Initial studies demonstrated that SK-N-SH cells exposed to thimerosal
underwent changes consistent with toxicity. The MTT results indicate that with
increasing time and concentrations of thimerosal, mitochondrial viability is
decreased, which can lead to cell death.

Additionally, LDH release occurred,

which is also indicative of cell death. As cell membrane integrity is lost, in either
necrosis or late apoptosis, LDH is released into the media surrounding the cells
(Loo and Rillema 1998).

Morphological changes observed in SK-N-SH cells

exposed to thimerosal included membrane blebbing, cell shrinkage, and
detachment from the plate, which are consistent with apoptosis.
studies confirmed that cells were undergoing apoptosis.

Fluorescent

Through use of a

membrane-permeable stain (Hoescht 33342) and a counterstain that was
membrane-impermeable (ethidium bromide), studies showed that nuclei were
condensed and fragmented. This condensation and fragmentation occurred while
the cellular membrane was still intact, which is characteristic of apoptosis (Lincz,
1998).

Thimerosal-induced toxicity in the SK-N-SH cell line occurred at

concentrations similar to those used in studies with other cell lines (James et al.,
2005; Parran et al., 2005; Makani et al., 2002; Baskin et al., 2003; Yel et al., 2005).
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5.3 Apoptosis Studies

Our studies have indicated that following exposure to thimerosal, SK-NSH cells undergo apoptotic cell death. Morphological studies demonstrated that
cells shrink and display membrane blebbing (Figure 4.1), which are characteristic
of apoptosis (Lincz, 1998).

Additional studies using fluorescent microscopy

indicated that nuclear condensation and fragmentation were occurring while the
cellular membrane was still intact (Figure 4.4), which is also characteristic of
apoptosis (Lincz, 1998). Makani et al., (2002) showed apoptosis in Jurkat T cells
exposed to similar concentrations of thimerosal as used in our study. Several
studies have confirmed these findings in neuroblastoma cell lines similar to the
model used in the present study (Baskin et al., 2003; Parran et al., 2005; Yel et
al., 2005).
Apoptosis occurs through two main pathways:

intrinsic pathway and

extrinsic pathway, and studies in our lab have indicated that thimerosal-induced
neurotoxicity occurs through a mitochondrial-mediated pathway (Humphrey et al.,
2005). This intrinsic pathway is characterized by release of cytochrome c from
the mitochondria (Figure 4.6). Mitochondrial membrane changes due to factors
such as calcium alterations or oxidative stress can lead to release of cytochrome
c from the mitochondria.

Both of these events have been shown to occur

following thimerosal treatment (Ueha-Ishibashi et al., 2004a, 2004b, 2005; James
et al., 2005, Yel et al., 2005, Marcelo et al., 2006). Cytochrome c release is
followed by cleavage of caspase 9 (Figure 4.7), which then cleaves caspase 3
(Figure 4.8).
Our studies were the first to show that thimerosal-induced apoptosis is
mediated specifically through caspase 9, not caspase 8 (Humphrey et al., 2005).
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This observation was later confirmed in another neuroblastoma cell line by Yel et
al. (2005). Active caspase 3 then proceeds to cleave substrates that perpetuate
the apoptotic response. One such substrate is PARP. PARP is involved in
sensing DNA damage, and degradation of PARP by caspase 3 is another marker
of apoptosis (Figure 4.10).

By contrast, the activation of PARP can lead to

necrosis through the depletion of NAD+, which leads to inactivation of ion
channels followed by cell swelling (Scovassi and Diederich, 2004; Diefenbach
and Burkle, 2005). Yel et al. (2005) also found that thimerosal leads to cleavage
of PARP.

All our results, coupled with confirmatory results found by other

laboratories, indicate that thimerosal induces apoptosis through a mitochondrialmediated pathway.

However, further investigation led to more information

concerning the signaling pathways activated by thimerosal.

5.4 JNK/AP-1 Studies

Studies have shown that JNK activation is essential to neuronal apoptosis
(Davis, 2000; Karin and Gallagher 2005; Kim et al., 2005b; Kuan et al., 1999; Lei
and Davis 2003; Okuno et al., 2004; Yang et al., 1997). Additionally, reports have
shown that AP-1 activation and increases in cJun and cFos can be involved in
neuronal apoptosis (Sastry and Rao, 2000).

Our studies have shown that

thimerosal induces increases in phosphorylation of JNK and cJun, as well as
increases in levels of cJun and cFos.

Thimerosal also induced AP-1

transcriptional activity with the involvement of cJun, but not cFos. In determining
which components were essential to apoptosis, we found that JNK, but not cJun,
was necessary for thimerosal-induced apoptosis in SK-N-SH cells. Studies with
the TAM67 dominant negative show that when cJun is unable to activate
transcription, SK-N-SH cells treated with thimerosal still undergo apoptosis, as
shown by activation of caspase 9 and 3, and degradation of PARP. These results
suggest that cJun activation is not required for thimerosal-induced cell death.
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Therefore, the AP-1 transcription factor must have another role following this
environmental insult.
Following cellular damage, cells enter into a period of cell cycle arrest in
order to repair damage. Shaulian et al. (2000) found that induction of cJun is
required for re-entry into the cell cycle following UV damage.

In the case of

thimerosal exposure, we saw increases in levels of cJun, which can be increased
in response to AP-1 activation, occurring at a later time point than JNK and cJun
activation. This protein increase could be the result of an attempt by the cell to
prepare to re-enter the cell cycle following repair. cJun can stimulate re-entry into
the cell cycle through induction of cyclin D1, which drives cell proliferation, or
through repression of p21Cip1, which promotes p53 activity (Shaulian et al., 2000).
On the other hand, Shaulian and Karin (2002) suggest that the role of cJun in
apoptosis and survival might be more of a balancing act between cJun-mediated
induction of proapoptotic and antiapoptotic target genes, including FasL, Bcl3, and
Bim. Depending on cell type, the nature of the stress, duration of exposure, and
other active transcription factors, the balance may shift toward either survival or
apoptosis. Further studies will be needed to determine if either of these events is
occurring in response to thimerosal, since SK-N-SH cells treated with the mercurycontaining compound appear unable to successfully process the toxic insult, and
thus proceed down an apoptotic pathway. Additionally, studies have shown that
the requirement for c-Jun phosphorylation in JNK-mediated apoptosis is
dependent on the stress signal and the cell type (Yang et al., 1997; Behrens et al.,
1999; Hochedlinger et al., 2002). Additionally, Besirli and Johnson (2003) report
that c-Jun phosphorylation may be independent of JNK activation in DNA damageinduced apoptosis. However, in our studies we found that SP600125 was able to
block c-Jun phosphorylation (Figure 3.4), indicating that c-Jun phosphorylation was
JNK-mediated in response to thimerosal.
Our studies are the first to show that proapoptotic Bim levels are increased
in response to thimerosal treatment, and are decreased when cells were
pretreated with SP600125 but not when transfected with TAM67, indicating that
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perhaps JNK and Bim are interacting directly. JNK has been shown to activate
Bim through phosphorylation, allowing Bim to contribute to apoptosis by interaction
with other Bcl2 proteins (Becker et al., 2004; Harris and Johnson, 2001). Under
normal conditions, Bim is attached to LC8 in the dynein motor complex, but
translocates to the mitochondrial membrane when activated, wherein Bim interacts
with Bax/Bad, causing pore formation and cytochrome c release, ultimately leading
to apoptosis (Mollinedo and Gajate, 2003). According to Putcha et al. (2001) this
Bim-mediated apoptosis is specific to neuronal cells, and does not occur in
nonneuronal cells in the brain.

Previous studies in our lab have shown that

thimerosal-treated SK-N-SH neuroblastoma cells have increases in cytochrome c
release, so this interaction with Bim is a potential mechanism by which JNK could
be directly causing apoptosis in these cells. Additionally, Bim is an AP-1 target
gene, but after blocking AP-1 transcription, we still see increases in levels of Bim,
indicating that in SK-N-SH cells Bim levels may be increased in response to other
transcription factors, such as members of the Forkhead family (Gilley et al., 2003;
Sunters et al., 2003). Essers et al. (2004) found that JNK can phosphorylate
Forkhead transcription factors, leading to apoptotic cell death. Further studies will
need to be conducted to determine both the significance of the AP-1 activation and
the substrates through which JNK is mediating intrinsic apoptotic cell death,
including the investigation of the JNK/Bim interaction.

5.5 JNK/Oxidative Stress Studies

We have shown in our laboratory that thimerosal induces oxidative stress
in the SK-N-SH neuroblastoma cell line (Marcelo et al., 2006). Other studies
have also found that thimerosal induces oxidative stress (Kim et al., 2002; Baskin
et al., 2003; James et al., 2005; Yel et al., 2005). Baskin et al. (2003) suggest
that free radicals may be involved in thimerosal-induced damage to the cell
membrane. Inorganic and organic mercurials, including thimerosal, have been
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shown to increase ROS and induce a state of “oxidative stress” in numerous cell
types; however, it is unknown whether this is a direct effect of the metal. Studies
have shown that thimerosal causes release of calcium from intracellular stores
followed by an influx of extracellular calcium (Gericke et al., 1993; Elferink,
1999), which can lead to an increase in ROS and RNS production in the
mitochondria. Both ROS and RNS have been shown to cause apoptotic cell
death (McGowan et al., 1996; Szabo, 1996; Cai and Jones, 1998; Chung et al.,
2001).

The ROS/RNS can directly interact with macromolecules such as

proteins and nucleic acids, leading to perturbations of vital cellular functions,
which may result in cell death.
Our studies have shown that thimerosal-induced apoptosis is JNKdependent. We have also shown that antioxidants could attenuate thimerosalinduced apoptosis (Marcelo et al., 2006). Apoptosis involving the JNK signaling
pathway has been shown to be redox-sensitive, so our goal was to determine if
the oxidative stress component of thimerosal-induced apoptosis was upstream of
JNK or part of a separate pathway. Through the use of antioxidants, we found
that both TX and NAC cause a transient increase in p-JNK in comparison to
thimerosal alone. By 24 h the antioxidant pretreatment led to a decrease in pJNK in comparison to thimerosal alone. Many studies have shown that oxidative
stress can act upstream of JNK (Bruckner et al., 2003; Soh et al., 2000; Choi et
al., 1999; Garcia-Fernandez et al., 2002; Kamata et al., 2005).
Choi et al. 1999 reported that they were able to attenuate the oxidative
stress-induced JNK activation through the use of NAC. In our studies we found
that both TX and NAC decrease JNK activation as well. However, we found that
antioxidant pretreatment caused p-JNK levels to rise following thimerosal
treatment before they ultimately were decreased over time. Most studies with
JNK and antioxidants indicate that reducing the oxidative stress subsequently
reduces the JNK activation. Studies have shown that this decrease could be due
to the inhibition of MAPK phosphatases (Kamata et al., 2005). On the contrary,
few studies have found that antioxidants cause increases in p-JNK. Studies with
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the green tea antioxidant (-)-epigallocatechin-3-gallate (EGCG) have shown that
EGCG can activate the JNK pathway (Chen et al., 2000; Kim et al., 2005a).
However, Kim et al. (2005) found that oxidative stress actually increases
following EGCG administration, so it must be altering redox status without having
an antioxidant effect. The mechanism remains to be discovered. Additionally,
the EGCG effect may be cell line specific, as Balasubramanian et al. (2002)
found that EGCG acts through p38, not JNK or ERK, in human keratinocytes.
From these pieces of information, we could speculate that in the process
of attenuating thimerosal-induced neurotoxicity through the use of antioxidants,
the initial altering of the redox status has the short-lived effect of increasing JNK
activation before eventually decreasing levels of p-JNK, and this effect could be a
stabilizing effect on p-JNK, perhaps through effects on MAPK phosphatases or
possibly through an overall stabilizing effect on the cell, such as when it enters
cell cycle arrest to repair thimerosal-induced damage. Finally, this effect could
be a differential phosphorylation of JNK; by reducing the apoptotic response with
antioxidants, the cell could be responding to other factors, such as the serum in
the medium.

5.6 Summary

We have shown that thimerosal can cause mitochondrial-mediated
apoptosis in a human neuroblastoma cell line. To our knowledge, this is the first
study to chronologically show the mitochondrial, cytosolic and nuclear events
associated with thimerosal-mediated toxicity in a non-differentiated neuronal
system. Our study is the first demonstration that thimerosal can induce activation
of JNK and AP-1 in the SK-N-SH neuroblastoma cell line.

We showed that

activation of cJun and AP-1 transcriptional activity following thimerosal treatment
does not appear to be involved in the induction of apoptosis, as demonstrated with
the studies using the cJun dominant negative. Furthermore, we were able to show
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that JNK is an essential upstream component of this pathway through use of the
JNK inhibitor SP600125.

This compound was able to attenuate activation of

downstream components of mitochondrial-mediated cell death and subsequently
protect the cells from apoptosis. We were also able to use antioxidants to show
that the JNK signaling pathway is redox sensitive, with the oxidative stress
component upstream of JNK.

The pathway determined by our studies is

presented in Figure 5.1, and Figure 5.2 displays a time line for events following 5
μM thimerosal treatment of SK-N-SH cells. These results are significant because
identifying specific signaling pathways activated in response to thimerosal
exposure presents pharmacological targets for attenuating potential toxicity in
patients exposed to thimerosal-containing products.

5.7 Future Studies

Many questions remain to be answered concerning the mechanism of
thimerosal-induced neurotoxicity. A concern that has arisen due to the presence
of thimerosal in vaccine is whether low levels of thimerosal are safe, and at what
concentration should patients be concerned.

Our studies use a range of

concentrations, but more studies could be undertaken with the concentrations at
the lowest range (nanomolar or lower) and for longer periods of time to assess the
toxic effects. It is important to see if very low concentrations have similar effects
over time, leading ultimately to the same toxic effects seen in our studies, or if
another biological response dominates, such as an effective survival response.
This information is important because effects seen with lower thimerosal
exposures could be different than with higher exposures.

Additionally, the

estimated 7-day half-life of ethylmercury leads to a lengthy exposure before the
compound is considered cleared from the body (approximately 28 days). It will be
important to learn if cells can repair damage following exposure to lower levels of
thimerosal, since we have demonstrated that a stress response is mounted by the
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SK-N-SH cells after treatment. Investigating survival signaling following thimerosal
treatment, along with the effects of these lower concentrations over time, could
lead to more information concerning the potential toxic effects of thimerosal in
vaccines.
Further investigation into the upstream and downstream components of the
JNK signaling pathway could also yield beneficial information concerning
thimerosal toxicity by providing more targets for development of drugs to attenuate
or alleviate the potential toxic effects. Components upstream of JNK have not
been elucidated in relation to thimerosal-induced neurotoxicity. MAPKKK (ASK1)
and MAPKK (MKK4/7) are important starting points, but other candidates for
activation of JNK signaling may by the small GTPases. Additionally, it will be
necessary to determine if any of these are signaling intermediaries between
thimerosal-induced oxidative stress and JNK signaling, and if they are not, then
are some other molecules, such as H2O2 or 4HNE, acting to activate JNK.
Downstream components of the pathway may also be targets for reducing toxicity.
These targets may include transcription factors other than AP-1, such as Forkhead
transcription factors, or gene that JNK signaling may be targeting. Microarray
studies using SP600125 in conjunction with thimerosal treatment may provide
important clues to JNK-mediated gene alterations.

These potential genetic

changes may also lead to information concerning other signaling pathways that
may be interacting with the JNK pathway following thimerosal treatment. Signaling
pathways are not isolated, with cross-talk between pathways occurring regularly.
Investigation into other signaling pathways that are interacting with JNK, and
information about regulation of those pathways may provide additional targets for
reducing potential toxic effects of thimerosal.
Gathering this mechanistic information from cell line such as the SK-N-SH
neuroblastoma cell line provides a springboard to study thimerosal-induced
neurotoxicity in an animal model. Animal studies using thimerosal are few, and
many concentration solely on the immune system and not on toxicity. However,
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moving these studies into an animal model is an important step in clarifying what is
happening in humans exposed to thimerosal.

The studies conducted with

autoimmune-sensitive mice have given toxicologists a model to use in studying
thimerosal-induced neurotoxicity. Using a model that is known to be sensitive to
thimerosal, studies can be undertaken that determine if effects seen in the SK-NSH cell line are occurring in vivo. Studies could investigate if oxidative stress is
increased, if JNK signaling is activated, if apoptosis is occurring, and if it is
mediated by the same mechanism as in the cell line. Answering these questions
would provide a wealth of information that could be used to study mechanisms by
which neurotoxicity could be alleviated in patients exposed to thimerosal.
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Figure 5.2. Time line for events following 5 μM thimerosal
treatment of SK-N-SH cells.

98

Bibliography

Ali SF, LeBel CP, Bondy SC. Reactive oxygen species formation as a biomarker
of methylmercury and trimethyltin neurotoxicity.
Neurotoxicology
1992;13(3):637-48.
Allen JW, El-Oqayli H, Aschner M, Syversen T, Sonnewald U. Methylmercury has
a selective effect on mitochondria in cultured astrocytes in the presence of
[U-13C]glutamate. Brain Res 2001;908(2):149-54.
Anderson AJ, Su JH, Cotman CW. DNA damage and apoptosis in Alzheimer’s
disease: colocalization with c-Jun immunoreactivity, relationship to brain
area, and effect of postmortem delay. J Neurosci 1996;16(5):1710-9.
Araragi S, Kondoh M, Kawase M, Saito S, Higashimoto M, Sato M. Mercuric
chloride induces apoptosis via a mitochondrial-dependent pathway in
human leukemia cells. Toxicology 2003;184(1):1-9.
Aschner M, Aschner JL. Mercury neurotoxicity: mechanisms of blood-brain barrier
transport. Neurosci Biobehav Rev 1990;14(2):169-76.
Balasubramanian S, Efimova T, Eckert R. Green tea polyphenol stimulates a Ras,
MEKK1, MEK3, and p38 cascade to increase activator protein 1 factordependent involucrin gene expression in normal human keratinocytes. J
Biol Chem 2002;277(3):1828-36.
Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines.
Pediatrics 2001;107(5):1147-54.
Barregard L, Sallsten G, Conradi N. Tissue levels of mercury determined in a
deceased worker after occupational exposure. Int Arch Occup Environ
Health 1999;72(3):169-73.
Baskin DS, Ngo H, Didenko VV. Thimerosal induces DNA breaks, caspase-3
activation, membrane damage, and cell death in cultured human neurons
and fibroblasts. Toxicol Sci 2003;74(2):361-8.

99

Becker EBE, Howell J, Kodama Y, Barker PA, Bonni A. Characterization of the cJun N-terminal kinase-BimEL signaling pathway in neuronal apoptosis. J
Neurosci 2004;24(40):8762-70.
Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun
regulates stress-induced apoptosis and cellular proliferation. Nat Genet.
1999;21(3):326-9.
Ben-Ozer EY, Rosenspire AJ, McCabe MJ Jr, Worth RG, Kindzelskii AL, Warra
NS, Petty HR. Mercuric chloride damages cellular DNA by a non-apoptotic
mechanism. Mutat Res 2000;470(1):19-27.
Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, Xu W, Leisten JC,
Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW.
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc
Natl Acad Sci USA 2001;98(24):13681-6.
Besirli CG, Johnson,Jr EM. JNK-independent activation of c-Jun during neuronal
apoptosis induced by multiple DNA-damaging agents. J Biol Chem
2003;278(25):22357-66.
Blair AMJN, Clark B, Clarke AJ, Wood P. Tissue concentrations of mercury after
chronic dosing of squirrel monkeys with thimerosal.
Toxicology
1975;3(2):171-6.
Bouillet P, Zhang LC, Huang DCS, Webb GC, Bottema CDK, Shore P, Eyre HJ,
Sutherland GR, Adams JM. Gene structure, alternative splicing, and
chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mammalian
Genome 2001;12(2):163-8.
Brawer JR, McCarthy GF, Gornitsky M, Frankel D, Mehindate K, Schipper HM.
Mercuric chloride induces a stress response in cultured astrocytes
characterized by mitochondrial uptake of iron.
Neurotoxicology
1998;19(6):767-76.
Brichese L, Cazettes G, Valette A. JNK is associated with Bcl-2 and PP1 in
mitochondria: paclitaxel induces its activation and its association with the
phosphorylated form of Bcl-2. Cell Cycle. 2004;3(10):1312-9.
Brown PH, Chen TK, Birrer MJ. Mechanism of action of a dominant negative
mutant of c-Jun. Oncogene 1994;9(3):791-9.
Bruckner SR, Perry G, Estus S. 4-hydroxynonenal contributes to NGF withdrawalinduced neuronal apoptosis. J Neurochem 2003;85(4):999-1005.
100

Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson, T.
Comparison of blood and brain mercury levels in infant monkeys exposed
to methylmercury or vaccines containing thimerosal. Environ Health
Perspect 2005;113(8):1015-21.
Butterfield L, Zentrich E, Beekman A, Heasley LE. Stress- and cell typedependent regulation of transfected c-Jun N-terminal kinase and mitogenactivated protein kinase kinase isoforms. Biochem J 1999;338(Pt 3):681-6.
Cai J, Jones DP. Superoxide in apoptosis. Mitochondrial generation triggered
by cytochrome c loss. J Biol Chem 1998;273(19):11401-4.
Chao E, Gierthy JF, Frenkel GD. A comparative study of the effects of mercury
compounds on cell viability and nucleic acid synthesis in HeLa cells.
Biochem Pharmacol 1984;33(12):1941-5.
Chen C, Rong Y, Owuor ED, Kong ANT. Activation of antioxidant-response
element (ARE), mitogen-activated protein kinases (MAPKs) and caspases
by major green tea polyphenol components during cell survival and death.
Arch Pharm Res 2000;23(6):605-12.
Chinopoulos C, Adam-Vizi V. Calcium, mitochondria and oxidative stress in
neuronal pathology. FEBS J 2006;273(3):433-50.
Choi BH, Yee S, Robles M. The effects of glutathione glycoside in methyl mercury
poisoning. Toxicol Appl Pharmacol 1996;141(2):357-64.
Choi W-S, Yoon S-Y, Oh TH, Choi E-U, O’Malley KL, Oh YJ. Two distinct
mechanisms are involved in 6-hydroxydopamine- and MPP+-induced
dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J
Neurosci Res 1999;57(1):86-94.
Chung HT, Pae HO, Choi BM, Billiar TR, Kim YM. Nitric oxide as a bioregulator
of apoptosis. Biochem Biophys Res Commun 2001;282(5):1075-9.
Clarkson TW. The three modern faces of mercury.
Perspectives 2002;110(Suppl 1):11-23.

Environmental Health

Clarkson TW, Magos L, Myers GJ. The toxicology of mercury—current exposures
and clinical manifestions. New Eng J Med 2003;349(18):1731-7.
Clements CJ, Ball LK, Ball R, Pratt RD. Thimerosal in vaccines: Is removal
warranted? Drug Saf 2001;24(8):567-74.

101

Counter SA, Buchanan LH. Mercury exposure in children: a review. Toxicol Appl
Pharmacol 2004;198(2):209-30.
Davis RJ. Signal Transduction by the JNK group of MAP kinases.
2000;103(2):239-52.

Cell

Debbasch C, Brignole F, Pisella P-J, Warnet J-M, Rat P, Baudouin C. Quaternary
ammoniums and other preservatives’ contribution in oxidative stress and
apoptosis on Chang conjunctival cells.
Invest Ophthalmol Vis Sci
2001;42(3):642-52.
Diefenbach J, Burkle J. Introduction to poly(ADP-ribose) metabolism. Cell Mol
Life Sci 2005;62(7-8):721-30.
Diner B, Brenner B. Mercury toxicity.
October 4, 2004.
Available at
http://www.emedicine.com/EMERG/topic813.htm. Accessed April 4, 2005.
Duhr EF, Pendergrass JC, Slevin JT, Haley BE. HgEDTA complex inhibits GTP
interactions with the E-site of brain beta-tubulin. Toxicol Appl Pharmacol
1993;122(2):273-80.
Elferink JGR. Thimerosal: a versatile sulfhydryl reagent, calcium mobilizer, and cell
function-modulating agent. General Pharmacology 1999;33(1):1-6.
Essers MAG, Weijzen S, de Vries-Smits AMM, Saarloos I, de Ruiter ND, Bos JL,
Burgering BMT. FOXO transcription factor activation by oxidative stress
mediated by the small GTPase Ral and JNK. EMBO J 2004;23(24):480212.
Food and Drug Administration web site. Mercury in Drug and Biologic Products.
Available at: http://www.fda.gov/cder/fdama/mercury300.htm. Accessed
January 23, 2006.
Food and Drug Administration web site. Thimerosal in vaccines. Available at
http://www.fda.gov/cber/vaccine/thimerosal.htm.
Accessed October 7,
2004.
Fournie GJ, Saoudi A, Druet P, Pelletier L. Th2-type immunopathological
manifestations induced by mercury chloride or gold salts in the rat: signal
transduction pathways, cellular mechanisms and genetic control.
Autoimmunity Reviews 2002;1(4):205-12.
Friberg L, Mottet NK. Accumulation of methylmercury and inorganic mercury in
the brain. Biol Trace Element Res 1989;21:201-6.
102

Garcia-Fernandez LF, Losada A, Alcaide V, Alvarez AM, Cuadrado A, Gonzalez L,
Nakayama K, Nakayama KI, Fernandez-Sousa JM, Munoz A, SanchezPuelles JM. Aplidin induces the mitochondrial apoptotic pathway via
oxidative stress-mediated JNK and p38 activation and protein kinase C
delta. Oncogene 2002;21(49):7533-44.
Gasset AR, Itoi M, Ishii Y, Ramer RM. Teratogenicities of ophthalmic drugs. II.
Teratogenicities and tissue accumulation of thimerosal. Arch Ophthalmol
1975;93(1):52-5.
Gericke M, Droogmans G, Nilius B. Thimerosal induced changes in intracellular
calcium in human endothelial cells. Cell Calcium 1993;14(3):201-7.
Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene
expression and promote apoptosis in sympathetic neurons. J Cell Biol
2003;162(4):613-22.
Guo TL, Miller MA, Shapiro IM, Shenker BJ. Mercuric chloride induces apoptosis
in human T lymphocytes: evidence of mitochondrial dysfunction. Toxicol
Appl Pharmacol 1998;153(2):250-7.
Hansson M, Djerbi M, Rabbani H, Mellstedt H, Gharibdoost F, Hassan M, DePierre
JW, Abedi-Valugerdi M. Exposure to mercuric chloride during the induction
phase and after the onset of collagen-induced arthritis enhances
immune/autoimmune responses and exacerbates the disease in DBA/1
mice. Immunology 2005;114(3):428-37.
Haggqvist B, Havarinasab S, Bjorn E, Hultman P. The immunosuppressive effect
of methylmercury does not preclude development of autoimmunity in
genetically susceptible mice. Toxicology 2005;208(1):149-64.
Harris CA, Johnson, Jr. EM. BH3-only Bcl-2 family members are coordinately
regulated by the JNK pathway and require Bax to induce apoptosis in
neurons. J Biol Chem 2001;276(41):37754-60.
Harry GJ, Harris MW, Burka LT. Mercury concentrations in brain and kidney
following ethylmercury, methylmercury, and thimerosal administration to
neonatal mice. Toxicol Lett 2004;154(3):183-9.
Hatzelmann A, Haurand M, Ullrich V. Involvement of calcium in the thimerosalstimulated formation of leukotriene by fMLP in human polymorphonuclear
leukocytes. Biochem Pharmacol 1990;39(3):559-67.

103

Havarinasab S, Lambertsson L, Qvarnstrom J, Hultman P. Dose-response study
of thimerosal-induced murine systemic autoimmunity.
Toxicol Appl
Pharmacol 2004;194(2):169-79.
Havarinasab S, Haggqvist B, Bjorn E, Pollard KM, Hultman P.
Immunosuppressive and autoimmune effects of thimerosal in mice. Toxicol
Appl Pharmacol 2005;204(2):109-21.
Havarinasab S, Hultman P. Organic mercury compounds and autoimmunity.
Autoimmun Rev 2005;4(5):270-5.
Hochedlinger K, Wagner EF, Sabapathy K. Differential effects of JNK1 and JNK2
on signal specific induction of apoptosis. Oncogene 2002;21(15):2441-5.
Hornig M, Chian D, Lipkin WI. Neurotoxic effects of postnatal thimerosal are
mouse strain dependent. Mol Psychiatry 2004;9(9):833-45.
Humphrey ML, Cole MP, Pendergrass JC, Kiningham KK. Mitochondrial mediated
thimerosal-induced apoptosis in a human neuroblastoma cell line (SK-NSH). Neurotoxicology 2005;26(3):407-16.
James SJ, Slikker III W, Melnyk S, New E, Pogribna M, Jernigan S. Thimerosal
neurotoxicity is associated with glutathione depletion: protection with
glutathione precursors. Neurotoxicology 2005;26(1):1-8.
Kakita A, Wakabayashi K, Su M, Sakamota M, Ikuta F, Takahashi H. Distinct
pattern of neuronal degeneration in the fetal rat brain induced by
consecutive transplacental administration of methylmercury. Brain Res
2000;859(2):233-9.
Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen
species promote TNFα-induced death and sustained JNK activation by
inhibiting MAP kinase phosphatases. Cell 2005;120(5):649-61.
Karin M, Gallagher E. From JNK to pay dirt: Jun kinases, their biochemistry,
physiology and clinical importance. IUBMB Life 2005;57(4/5):283-95.
Katsen AD, Vollmar B, Mestres-Ventura P, Menger MD. Cell surface and nuclear
changes during TNF-alpha-induced apoptosis in WEHI 164 murine
fibrosarcoma cells. A correlative light, scanning, and transmission electron
microscopical study. Virchows Arch 1998;433(1):75-83.
Kim E, Kim JH, Kim HS, Ryu SH, Suh P. Thimerosal stimulates focal adhesion
kinase and cytoskeletal changes by redox modulation. Biochim Biophys
Acta 2002;1593(1):9-15.
104

Kim M, Murakami A, Kawabata K, Ohigashi H. (-)-Epigallocatechin-3-gallate
promotes pro-matrix metalloproteinase-7 production via activation of the
JNK1/2 pathway in HT-29 human colorectal cancer cells. Carcinogenesis
2005a;26(9):1553-62.
Kim SD, Moon CK, Eun S-Y, Ryu PD, Jo SA. Identification of ASK1, MKK4, JNK,
c-Jun, and caspase-3 as a signaling cascade involved in cadmium-induced
neuronal apoptosis. Biochem Biophys Res Commun 2005b;328(1):326-34.
Kinoshita Y, Ohnishi A, Kohshi K, Yokota A. Apparent diffusion coefficient on rat
brain and nerves intoxicated with methylmercury.
Environ Res
1999;80(4):348-54.
Koller LD. Immunosuppression produced by lead, cadmium, and mercury. Am J
Vet Res 1973;34(11):1457-8.
Kuan C-Y, Yang DD, Roy DRS, Davis RJ, Rakic P, Flavell RA. The Jnk1 and Jnk2
protein kinases are required for regional specific apoptosis during early
brain development. Neuron 1999;22(4):667-76.
Kunimoto M. Methylmercury induces apoptosis of rat cerebellar neurons in
primary culture. Biochem Biophys Res Commun 1994;204(1):310-7.
Kutuk O, Pedrech A, Harrison P, Basaga H. Pramanicin induces apoptosis in
Jurkat leukemia cells: a role for JNK, p38 and caspase activation.
Apoptosis. 2005;10(3):597-609.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 1970;227(5259):680-5.
Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an
influenza vaccine. Ann Allergy Asthma Immunol 2005;94(1):90-4.
Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family
induces Bax-dependent apoptosis.
Proc Nat Acad Sci USA
2003;100(5):2432-7.
Leonard SS, Harris GK, Shi X. Metal-induced oxidative stress and signal
transduction. Free Radic Biol Med 2004;37(12):1921-42.
Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma
2000;17(10):871-90.

105

Lincz LF. Deciphering the apoptotic pathway: all roads lead to death. Immunol
Cell Biol 1998;76(1):1-19.
Loo DT, Rillema JR. Measurement of cell death. Methods Cell Biol 1998;57:25164.
Magos L. Review on the toxicity of ethylmercury, including its presence as a
preservative in biological and pharmaceutical products. J Appl Toxicol
2001;21(1):1-5.
Magos L, Brown AW, Sparrow S, Bailey E, Snowden RT, Skipp WR. The
comparative toxicology of ethyl- and methylmercury.
Arch Toxicol
1985;57(4):260-7.
Makani S, Gollapudi S, Yel L, Chiplunkar S, Gupta S. Biochemical and molecular
basis of thimerosal-induced apoptosis in T cells: a major role of
mitochondrial pathway. Genes Immun 2002;3(5):270-8.
Mansour MM, Dyer NC, Hoffman LH, Schulert AR, Brill AB. Maternal-fetal transfer
of organic and inorganic mercury via placenta and milk. Environmental
Research 1973;6(4)479-84.
Mansour MM, Dyer NC, Hoffman LH, Davies J, Brill AB. Placental transfer of
mercuric nitrate and methylmercury in the rat. Am J Obstet Gynecol
1974;119(4):557-62.
Marcelo A, Herdman ML, Cook C, Kiningham KK. N-Acetylcysteine (NAC) and
Trolox Attenuate Thimerosal-Induced Oxidative Stress and Apoptosis-19th
Annual Research Day, MUSOM-March 2006.
Martin F, Gualberto A, Sobrino F, Pintado E. Thimerosal induces calcium
mobilization, fructose 2,6-bisphosphate synthesis and cytoplasmic
alkalinization in rat thymus lymphocytes.
Biochim Biophys Acta
1991;1091(1):110-4.
McCabe Jr MJ, Eckles KG, Langdon M, Clarkson TW, Whitekus MJ, Rosenspire
AJ. Attenuation of CD95-induced apoptosis by inorganic mercury: caspase3 is not a direct target of low levels of Hg2+. Toxicol Lett 2005;155(1):16170.
McGowan AJ, Ruiz-Ruiz MC, Gorman AM, Lopez-Rivas A, Cotter TG. Reactive
oxygen intermediate(s) (ROI): common mediator(s) of poly(ADP-ribose)
polymerase (PARP) cleavage and apoptosis. FEBS Lett 1996;392(3):299303.
106

Meyer M, Pahl HL, Baeuerle PA. Regulation of the transcription factors NF-κB and
AP-1 by redox changes. Chem Biol Interact 1994;91(2-3):91-100.
Mielke K, Damm A, Yang DD, Herdegen T. Selective expression of JNK isoforms
and stress-specific JNK activity in different neural cell lines. Brain Res Mol
Brain Res 2000;75(1):128-37.
Mercury in Drug and Biologic Products. U.S. Food and Drug Administration web
site-http://www.fda.gov/cder/fdama/mercury300.htm. Updated September
14, 2004. Accessed January 23, 2006.
Mollinedo F, Gajate C.
Microtubules, microtubule-interfering agents and
apoptosis. Apoptosis 2003;8(5):413-50.
Monnet-Tschudi F. Induction of apoptosis by mercury compounds depends on
maturation and is not associated with microglial activation. J Neurosci Res
1998;53(3):361-7.
Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ, Shirasaki
Y, Greenberg ME. β-Amyloid induces neuronal apoptosis via a mechanism
that involves the c-Jun N-terminal kinase pathway and the induction of Fas
ligand. J Neurosci 2001;21(19):7551-60.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application
to proliferation and cytotoxicity assays. J Immunol Methods 1983;65(12):55-63.
Moszczynski P. Immunological disorders in men exposed to metallic mercury
vapour. Cent Eur J Public Health. 1999 Feb;7(1):10-4.
Nagashima K, Fujii Y, Tsukamoto T, Nukuzuma S, Satoh M, Fujita M, Fujioka Y,
Akagi H. Apoptotic process of cerebellar degeneration in experimental
methylmercury intoxication of rats. Acta Neuropathol 1996;91(1):72-7.
Nielsen JB, Hultman P. Mercury-induced autoimmunity in mice. Environ Health
Perspect 2002;110(51):877-81.
Norseth T, Clarkson TW. Studies on the biotransformation of 203Hg-labeled methyl
mercury chloride in rats. Arch Environ Health 1970;21(6):717-27.
Okuno S, Saito A, Hayashi T, Chan PH. The c-Jun N-terminal protein kinase
signaling pathway mediates Bax activation and subsequent neuronal
apoptosis through interaction with Bim after transient focal cerebral
ischemia. J Neurosci 2004;24(36):7879-87.
107

Opitz H, Schweinsberg F, Grossmann T, Wendt-Gallitelli MF, Meyermann R.
Demonstration of mercury in the human brain and other organs 17 years
after metallic mercury exposure. Clin Neuropathol 1996;15(3):139-44.
Parran DK, Barker A, Ehrich M. Effects of thimerosal on NGF signal transduction
and cell death in neuroblastoma cells. Toxicol Sci 2005;86(1):132-40.
Pham CG, Papa S, Bubici C, Zazzeroni F, Franzoso G. Oxygen JNKies:
phosphatases overdose on ROS. Dev Cell 2005;8(4)452-4.
Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and
metabolism in infants receiving vaccines containing thiomersal: a
descriptive study. Lancet 2002;360(9347):1737-41.
Pollard KM, Hultman P. Effects of mercury on the immune system. Met Ions Biol
Syst 1997;34:421-40.
Putcha GV, Moulder KL, Golden JP, Bouillet P, Adams JA, Strasser A, Johnson,
Jr, EM. Induction of Bim, a proapoptotic BH3-only Bcl-2 family member, is
critical for neuronal apoptosis. Neuron 2001;29(3):615-28.
Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ, LaMarche
A, Maroney AC, Johnson, Jr EM. JNK-mediated Bim phosphorylation
potentiates Bax-dependent apoptosis. Neuron 2003;38(6):899-914.
Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer M, Akhmedov A, Hersberger M,
Eriksson U, Eberli FR, Becher B, Boren J, Chen M, Cybulsky MI, Moore KJ,
Freeman MW, Wagner EF, Matter CM, Luscher. Requirement of JNK2 for
scavenger receptor A-mediated foam cell formation in atherogenesis.
Science 2004;306(5701):1558-61.
Qvarnstrom J, Lambertsson L, Havarinasab S, Hultman P, Frech W.
Determination of methylmercury, ethylmercury, and inorganic mercury in
mouse tissues, following administration of thimerosal, by species-specific
isotope dilution GC-inductively coupled plasma-MS.
Anal Chem
2003;75(16):4120-4.
Sabapathy K, Hu Y, Kallunki T, Schreiber M, David JP, Jochum W, Wagner EF,
Karin M. JNK2 is required for efficient T-cell activation and apoptosis but
not for normal lymphocyte development. Curr Biol. 1999;9(3):116-25.
Sager PR, Syversen TL. Differential responses to methylmercury exposure and
recovery in neuroblastoma and glioma cells and fibroblasts. Exp Neurol
1984;85(2):371-82.
108

Sanfeliu C, Sebastia J, Kim, SU. Methylmercury neurotoxicity in cultures of human
neurons, astrocytes, neuroblastoma cells. Neurotoxicology 2001;22(3):31727.
Sanfeliu C, Sebastia J, Cristofol R, Rodriguez-Farre.
Neurotoxicity of
organomercurial compounds. Neurotox Res 2003;5(4):283-306.
Sarafian TA, Vartavarian L, Kane DJ, Bredesen DE, Verity MA. Bcl-2 expression
decreases methyl mercury-induced free-radical generation and cell killing in
a neural cell line. Toxicol Lett 1994;74(2):149-55.
Sastry PS, Rao KS.
2000;74(1):1-20.

Apoptosis and the nervous system.

J Neurochem

Scovassi AI, Diederich M. Modulation of poly(ADP-ribosylation) in apoptotic cells.
Biochem Pharmacol 2004;68(6):1041-7.
Shaulian E, Karin M. AP-1 in cell proliferation and survival.
2001;20(19):2390-400.

Oncogene

Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol
2002;4(5):E131-6.
Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, and Karin M. The
mammalian UV response: c-Jun induction is required for exit from p53imposed growth arrest. Cell 2000;103(6):897-907.
Shenker BJ, Guo TL, Shapiro IM. Low-level methylmercury exposure causes
human T-cells to undergo apoptosis: evidence of mitochondrial dysfunction.
Environ Res 1998;77(2):149-59.
Shenker BJ, Guo TL, Shapiro IM. Mercury-induced apoptosis in human lymphoid
cells:evidence that the apoptotic pathway is mercurial species dependent.
Environ Res 2000;84(2):89-99.
Shenker BJ, Guo TL, O I, Shapiro IM. Induction of apoptosis in human T-cells by
methyl mercury: temporal relationship between mitochondrial dysfunction
and loss of reductive reserve. Toxicol Appl Pharmacol 1999;157(1):23-35.
Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional
cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63
and 73. Nature 1991;354(6353):494-6.

109

Soh Y, Jeong K-S, Lee IJ, Bae M-A, Kim Y-C, Song BJ. Selective activation of the
c-Jun N-terminal protein kinase pathway during 4-hydroxynonenal-induced
apoptosis of PC12 cells. Mol Pharmacol 2000;58(3):535-41.
Sorg O, Schilter B, Honegger P, Monnet-Tschudi F. Increased vulnerability of
neurons and glial cells to low concentrations of methylmercury in a
prooxidant situation. Acta Neuropathol 1998;96(6):621-7.
Squier MK, Cohen JJ. Assays of apoptosis. Methods Mol Biol 2000;144:327-37.
Stajich GV, Lopez GP, Harry SW, Sexson WR. Iatrogenic exposure to mercury
after hepatitis B vaccination in preterm infants.
J Pediatrics
2000;136(5):679-81.
Steinmuller L, Cibelli G, Moll JR, Vinson C, Thiel G. Regulation and composition
of activator protein –1 (AP-1) transcription factors controlling collagenase
and c-Jun promotor activities. Biochem J 2001;360(Pt 3):599-607.
Stoiber T, Degen GH, Bolt HM, Unger E. Interaction of mercury(II) with the
microtubule cytoskeleton in IMR-32 neuroblastoma cells. Toxicol Lett
2004;151(1):99-104.
Suda I, Totoki S, Takahashi H. Degradation of methyl and ethyl mercury into
inorganic mercury by oxygen free radical producing systems: involvement
of hydroxyl radical. Arch Toxicol 1991;65(2):129-34.
Suda I, Totoki S, Uchida T, Takahashi H. Degradation of methyl and ethyl
mercury into inorganic mercury by various phagocytic cells. Arch Toxicol
1992;66(1):40-4.
Sumbayev VV, Yasinska IM. Regulation of MAP kinase-dependent apoptotic
pathway: implication of reactive oxygen and nitrogen species. Arch
Biochem Biophys 2005;436(2):406-12.
Sun Y, Oberley LW. Redox regulation of transcriptional activators. Free Rad Biol
Med 1996;21(3):335-48.
Sunters A, de Mattos SF, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA,
Coffer PJ, Medema RH, Coombes RC, Lam EWF. Fox03a transcription
regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell
lines. J Biol Chem 2003;278(50):49795-805.
Szabo C. DNA strand breakage and activation of poly-ADP ribosyltransferase: a
cytotoxic pathway triggered by peroxynitrite. Free Radic Biol Med
1996;21(6):855-69.
110

Thevenod F, Friedmann JM, Katsen AD, Hauser IA. Up-regulation of multidrug
resistance P-glycoprotein via nuclear factor-kappaB activation protects
kidney proximal tubule cells from cadmium- and reactive oxygen speciesinduced apoptosis. J Biol Chem 2000;275(3):1887-96.
Toimela T, Tahti H. Mitochondrial viability and apoptosis induced by aluminum,
mercuric mercury and methylmercury in cell lines of neural origin. Arch
Toxicol 2004;78(10):565-74.
Tong L, Toliver-Kinsky T, Taglialatela G, Werrbach-Perez K, Wood T, Perez-Polo
JR. Signal Transduction in Neuronal Death. J Neurochem 1998;71(2):44759.
Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones S,
Flavell RA, Davis RJ. Requirement of JNK for stress-induced activation of
the cytochrome c-mediated death pathway. Science 2000;288(5467):8704.
Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y, Yoshioka K,
Masuyama N, Gotoh Y. JNK promotes Bax translocation to mitochondria
through phosphorylation of 14-3-3 proteins. EMBO J. 2004;23(8):1889-99.
Ueha-Ishibashi T, Oyama Y, Nakao H, Umebayashi C, Nishizaki Y, Tatsuishi T,
Iwase K, Murao K, Seo H. Effect of thimerosal, a preservative in vaccines,
on intracellular Ca2+ concentration of rat cerebellar neurons. Toxicology
2004a;195(1):77-84.
Ueha-Ishibashi T, Tatsuishi T, Iwase K, Nakao H, Umebayashi C, Nishizaki Y,
Nishimura, Oyama Y, Hirama S, Okano Y. Property of thimerosal-induced
decrease in cellular content of glutathione in rat thymocytes: a flow
cytometric study with 5-chloromethylfluorescein diacetate. Toxicol in Vitro
2004b;18(5):563-9.
Ueha-Ishibashi T, Oyama Y, Nakao H, Umebayashi C, Hirama S, Sakai Y, Ishida
S, Okano Y. Flow-cytometric analysis on cytotoxic effect of thimerosal, a
preservative in vaccines, on lymphocytes dissociated from rat thymic
glands. Toxicol in Vitro 2005;19(2):191-8.
Vahter M, Mottet NK, Friberg L, Lind B, Shen DD, Burbacher T. Speciation of
mercury in the primate blood and brain following long-term exposure to
methyl mercury. Toxicol Appl Pharmacol 1994;124(2):221-9.
Valencia A, Moran J. Reactive oxygen species induce different cell death
mechanisms in cultured neurons. Free Rad Biol Med 2004;36(9):1112-25.
111

Waetzig V, Herdegen T. Context-specific inhibition of JNKs: overcoming the
dilemma of protection and damage. Trends Pharmacol Sci 2005;26(9):45561.
Waly M, Olteanu H, Banerjee R, Choi S-W, Mason JB, Parker BS, Sukumar S,
Shim S, Sharma A, Benzecry JM, Power-Charnitsky V-A, Deth RC.
Activation of methionine synthase by insulin-like growth factor-1 and
dopamine: a target for neurodevelopmental toxins and thimerosal.
Molecular Psychiatry 2004;9(4):358-70.
Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, Rakic P, and
Flavell RA. Absence of excitotoxicity-induced apoptosis in the
hippocampus of mice lacking the Jnk3 gene. Nature 1997;389(6653):86570.
Yel L, Brown LE, Su K, Gollapudi S, Gupta S. Thimerosal induced neuronal cell
apoptosis by causing cytochrome c and apoptosis-inducing factor release
from mitochondria. Int J Mol Med 2005;16(6):971-7.
Zhang X, Moilanen E, Lahti A, Hamalainen M, Giembycz MA, Barnes PJ, Lindsay
MA, Kankaanranta H. Regulation of eosinophil apoptosis by nitric oxide:
role of c-Jun-N-terminal kinase and signal transducer and activator of
transcription 5. J Allergy Clin Immunol 2003;112(1):93-101.

112

Curriculum Vitae
Michelle L. Herdman
Contact Information
Address:

P.O. Box 567
Eleanor, WV 25070

Phone:

(304) 546-0315-cell
(304) 586-1067-home
(304) 696-7132-work

E-mail:
Education
2001-Present:
1993-1994:
1990-1994:

humphrey7@marshall.edu

Graduate Student working toward PhD in Biomedical Sciences,
Department of Pharmacology, Marshall University School of
Medicine (MUSOM), Huntington, West Virginia
Certificate of Completion, Rockingham Memorial Hospital
School of Medical Technology, Harrisonburg, Virginia
BS in Medical Technology, Bridgewater College, Bridgewater,
Virginia

Professional Experience
1998-2001:
Laboratory Supervisor-Evening/Midnight Shift-Charleston Area
Medical Center, Charleston, WV
1996-1998:
Medical Technologist-Charleston Area Medical Center
1994-1996:
Medical
Technologist-Rockingham
Memorial
Hospital,
Harrisonburg, VA
Research:
2001-Present:
Teaching:
03/06:
01/05 & 01/06:

MUSOM-Doctoral Student-Thesis project involves the role of
JNK/AP-1 in thimerosal-induced neurotoxicity
Medical Pharmacology course-lecture-Respiratory
Pharmacology
Medical Pharmacology course-led small group Patient Oriented
Problems Solving (POPS) session-“Pharmacokinetics Applied
to the Treatment of Asthma”

113

1996-2001:
1999:
1994-1996:
1995:

Trained new employees in laboratory techniques at Charleston
Area Medical Center
Assisted in development of course materials and taught 3-day
Softlab computer systems training sessions for laboratory
personnel at Charleston Area Medical Center
Trained students in laboratory techniques at Rockingham
Memorial Hospital School of Medical Technology
Lectured to students at Rockingham Memorial Hospital School
of Medical Technology -one hour lectures on “Complement”
and “Systemic Lupus Erythematosus”

Professional Affiliations and Activities
ASCP Certification-MT(ASCP)
AMWA-Member since 2002-earned Core Curriculum certificate in Editing/Writing2005
Graduate Student Organization, President 2004-05
Student Member of Society of Free Radical Biology and MedicineMember since 08/2005
Publications and Presentations
Publications:
Peer-Reviewed Journal Publications
•
•
•

Marcelo AJ, Herdman ML, Cook C, Stewart JC, Kiningham KK.
Antioxidant Attenuates Thimerosal-Induced Stress Response in a Human
Neuroblastoma Cell Line (SK-N-SH).-submitted to NeuroToxicology 03/06
Herdman ML, Marcelo A, Huang Y, Niles RM, Dhar S, Kiningham KK.
Thimerosal Induces Apoptosis in a Neuroblastoma Model Via the cJun NTerminal Kinase Pathway.-in press, Toxicological Sciences
Humphrey ML, Cole MP, Pendergrass JC, and Kiningham KK.
Mitochondrial Mediated Thimerosal-Induced Apoptosis in a Human
Neuroblastoma Cell Line (SK-N-SH). NeuroToxicology-June 2005

Abstracts
•

•
•

Herdman ML and Kiningham KK. Thimerosal-Induced Apoptosis Occurs
in a cJun N Terminal Kinase (JNK)-Dependent Manner in a Human
Neuroblastoma Cell Line (SK-N-SH)-19th Annual Research Day, MUSOMMarch 2006-chosen for oral presentation-won award for Best Basic
Science Oral Presentation
Marcelo A, Herdman ML, Cook C, Kiningham KK. N-Acetylcysteine
(NAC) and Trolox Attenuate Thimerosal-Induced Oxidative Stress and
Apoptosis-19th Annual Research Day, MUSOM-March 2006
Herdman ML and Kiningham KK. Thimerosal-Induced Activation of
Redox-Sensitive cJun N-Terminal Kinase (JNK) and Activator Protein-1
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•

•

•

•
•

•
•

(AP-1) Transcription Factors in a Neuroblastoma Cell Line-12th Annual
Meeting of the Society for Free Radical Biology and Medicine-November
2005-chosen for oral presentation
Davis T, Cook C, Humphrey ML, Marcelo A, Tassone M, Kiningham K,
Spitz D. Upregulation of Manganese Superoxide Dismutase Protein and
Activity by All-Trans Retinoic Acid (ATRA): Potential Roles of NFκB and
Retinoic Acid Receptors (RAR)-4th Annual WV-INBRE Summer Research
Symposium, Marshall University-August 2005
Humphrey ML, Huang Y, Niles, RM, Kiningham, KK. Thimerosal-Induced
Activation of the JNK/AP-1 Signaling Cascade: A Potential Pathway to
Neuronal Apoptosis-15th annual Sigma Xi Research Day, Marshall
University-April 2005
Marcelo A, Humphrey ML, Cook C, Stewart JC, Kiningham, KK.
Antioxidants Block Thimerosal-Induced Stress Response and Attenuate
Cellular Damage in a Human Neuroblastoma Cell Line (SK-N-SH)- 15th
Annual Sigma Xi Research Day, MUSOM-April 2005
Humphrey ML, Huang Y, Niles, RM, Kiningham, KK. Thimerosal-Induced
Activation of the JNK/AP-1 Signaling Cascade: A Potential Pathway to
Neuronal Apoptosis-18th Annual Research Day, MUSOM-March 2005
Marcelo A, Humphrey ML, Cook C, Stewart JC, Kiningham, KK.
Antioxidants Block Thimerosal-Induced Stress Response and Attenuate
Cellular Damage in a Human Neuroblastoma Cell Line (SK-N-SH)- 18th
Annual Research Day, MUSOM-March 2005
Marcelo A, Cook C, Humphrey ML, Kiningham KK. All-trans Retinoic
Acid (ATRA) Protects Against Cisplatin-Mediated Apoptosis-14th Annual
Sigma Xi Research Day, Marshall University-April 2004
Humphrey ML, Huang Y, Niles, RM, Kiningham, KK. Thimerosal Induces
Apoptosis in a Neuroblastoma Model:
Potential Role of AP-1
Transcription Factor-17th Annual Research Day, MUSOM-selected for oral
presentation-March 2004

Presentations:
•
•
•
•
•

Got Mercury?-Seminar presented to faculty and students, MUSOM-April
2005
Thimerosal Induces Apoptosis in a Neuroblastoma Model: Potential Role
of AP-1 Transcription Factor-Seminar presented to faculty and students,
MUSOM-April 2004
Does Thimerosal Induce Neurotoxicity?-Presented to Communications
Department undergraduates-Marshall University-Nov 2003
The Role of Thimerosal in Neurotoxicity-Presented to faculty and staff in a
Signal Transduction Workshop sponsored by the Department of
Biochemistry, MUSOM-Nov 2003
Bone Marrow Transplantation-Seminar to students and faculty, MUSOMApril 2002
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•
•

Patient Confidentiality-Inservice to employees at Charleston Area Medical
Center-April 2001
Point of Care Testing-Inservice to employees at Rockingham Memorial
Hospital-March 1994
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